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INTRODUCTION
I had always intended on attending Veterinary School, but when my mother was
diagnosed with an aggressive form of Breast Cancer in 2008 my eyes were opened to a career
path I had not considered. In August of 2015, I enrolled in the Biochemistry Graduate Program at
the University of New Hampshire with the personal goal of participating in cancer research.
When I arrived on campus I began exploring the various research opportunities. At this time, I
became familiar with the work of Research Professor, Dr. Vernon Reinhold who introduced me
to the field of Glycomics. My previous experience with glycomics had been a single brief lecture
in my undergraduate Biochemistry course. I was immediately intrigued by the vast and critical
influence glycosylation could have on cell function and human health and surprised by the lack
of attention these post-translational modifications received.
When I began my second rotation in the laboratory of Reproductive Physiologist, Dr.
David Townson, I was presented with previous Masters Student, Brian Sullivan’s, research
project investigating the functional role of cytokeratin intermediate filaments 8/18 (K8/18),
which had been previously noted to be up-regulated in more aggressive cervical cancers.
Through Brian’s work, the Townson group discovered that within the cervical cancer cell line,
HeLa cells, two cellular phenotypes could be identified; those expressing K8/18 and those
lacking K8/18 expression. The two phenotypes were separated by serial dilution in order to
analyze various parameters of cell survival and immune system evasion. The study supported the
hypothesis that reduced K8/18 expression increased cellular susceptibility to immune mediated
death, specifically by the cytokines Fas Ligand (FasL) and Tumor Necrosis Factor α (TNF-α).

ix

This work suggested that K8/18 filaments provided protection against immune mediated death,
subsequently allowing for the progression of neoplastic disease.
This work led me to ask the question, what is the mechanism that provides this
protection? Having just completed my rotation in the UNH Glycomics Center, I went to the
literature to determine if, and how, K8/18 filaments are glycosylated. I soon discovered Keratin
18 filaments are highly phosphorylated and glycosylated. However, this protein is not
glycosylated in the traditional branched chain formation but is O-linked β-Nacetylglucosaminylated (O-GlcNAcylated). This discovery led me down a winding and
fascinating path into a relatively new and exciting area of science. I initially used Brian’s work
as a jumping off point and began investigating the role of O-GlcNAcylation in cervical cancer
disease progression and metastasis. This led to my first publication, “O-GlcNAcylation enhances
the tumorigenic properties of cervical cancer cells in vitro.(Jaskiewicz, Hermawan, Parisi, &
Townson, 2017)” (Chapters 2 and 3).
Shortly after completing this work I was presented with the opportunity to move to the
University of Vermont (UVM) with Dr. Townson and the laboratory. I eagerly accepted the offer
and prepared to move. When we arrived at UVM, I spent several months working with Dr.
Townson to establish the new laboratory and explore new opportunities at the University.
Perhaps one of the most exciting components of this transition was the close proximity of the
main campus to the University of Vermont College of Medicine. This opened up a number of
resources that have furthered my research and training.

x

It was at this time that I contacted Dr. Elizabeth McGee, an OB/GYN research physician,
for guidance with continuing my research. After consulting with Dr. McGee, it was decided that
while the results of my first study were interesting and warranted further investigation, the
clinical relevance of studying O-GlcNAcylation in cervical cancer was not clear. However, OGlcNAcylation’s connection to diabetes encouraged us to transition to an endometrial cancer cell
model. Women with Type II Diabetes have a 2-3 fold increased risk of developing endometrial
cancer, and mRNA analysis of endometrial tumors showed an increase in the O-GlcNAc cycling
enzyme mRNA in the leading edge of tumors. This led to my second manuscript, “Hyper-OGlcNAcylation promotes Epithelial-Mesenchymal Transition in endometrial cancer cells,” which
is currently in revision for the journal, Oncotarget. (Chapter 4). Finally, my interest extended
from disease progression to possible treatment interference, and in my final manuscript I focused
on the impact hyper-O-GlcNAcylation may have on the efficacy of progesterone treatment to
reduce invasion and cell proliferation in endometrial cancer (Chapter 5).
Throughout my graduate student career, I was incredibly fortunate to be afforded the
independence to build a research project that both supported my interest in women’s health and
facilitated an interdisciplinary research education. I hope that you will recognize the unique
graduate experience that Dr. Townson supported and guided me through in the proceeding
chapters. As my graduate student career draws to an end, I look forward to continuing to explore
the fields of women’s reproductive health and glycobiology as a lifelong learner.
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ABSTRACT

DYSREGULATION OF O-LINKED β-N-ACETYLGLUCOSAMINE (O-GLCNAC)
CYCLING SUPPORTS TUMORIGENICITY OF CANCERS OF THE FEMALE
REPRODUCTIVE TRACT
by
Nicole Morin Jaskiewicz
University of New Hampshire, September, 2018

Hyper-O-GlcNAcylation of proteins is a subsequent artifact of metabolic disorder and is
indicative of many cancers, including cancers of the female reproductive tract. While the
incidence of most cancer types has been declining in the U.S., endometrial and cervical cancer
remain among the most common cancers diagnosed in women. Diabetic women have a 2-3 fold
increased risk of developing endometrial cancer, and tend to have more aggressive cases of
cervical cancer, however, the molecular aspects of these risks are not fully understood. This
study investigated the alteration of cellular O-GlcNAcylation of proteins as the potential
mechanistic connection between diabetes and tumorigenicity in cancers of the female
reproductive tract. The cervical cancer cell line (SiHa) and the endometrial cancer cell line
(Ishikawa) were utilized to study the effect of dysregulation of O-GlcNAcylation on the
proliferation, migration, invasion, and related molecular mechanisms. In cervical cancer, OGlcNAcylation was found to be an important regulator of tumorigenicity. Overall, inhibition of
O-GlcNAcylation (via the inhibitor, OSMI-1) in SiHa cells impaired cell proliferation (p<0.01)
and invasion (p<0.01) yet did not affect cell cycle progression. These effects occurred
xii

concomitantly with an alteration of cellular morphology, principally the disruption/decline of
K8/18 and β-actin filament expression. The results suggest O-GlcNAcylation regulates several
aspects of tumorigenesis in cervical cancer cells, and cytoskeletal proteins are among the targets.
Similarly, in endometrial cancer cells, hyper-O-GlcNAcylation (via 1μM Thiamet-G/ThmG or
25mM Glucose) enhanced the expression of EMT-associated genes (WNT5B and FOXC2), and
the E-Cadherin suppressor, Snail. Reorganization of actin filaments into stress filaments,
consistent with EMT, was also noted in ThmG-treated cells. Interestingly, Hypo-OGlcNAcylation (via 50 μM OSMI-1) also upregulated WNT5B, inferring that any disruption to
O-GlcNAc cycling impacts EMT. However, Hypo-O-GlcNAcylation reduced cellular
proliferation/migration and the expression of the pro-EMT genes (AHNAK, TGFB2, FGFBP1,
CALD1, TFPI2). Finally, Ishikawa cells were used to investigate the effect hyper-OGlcNAcylation on the efficacy of progesterone (P4) in therapy for endometrial cancer
proliferation and invasion. Ishikawa cells were exposed to ThmG, to induce hyper-OGlcNAcylation, and 100nM P4. P4 alone, significantly decreased cell proliferation, however, the
addition of ThmG, and subsequent hyper-O-GlcNAcylation, negated this affect, returning the
cells to control level proliferation (p<0.05). A similar pattern was noted in Matrigel invasion
assays, where Hyper-O-GlcNAcylation augmented invasion compared to P4 treatment alone,
both with and without progesterone treatment (p<0.05). Progesterone treatment has been shown
to induce the expression of p21 and p27, reducing cell growth. In this study, P4 maintained p21
expression and increased p27 expression, however, ThmG decreased p27 expression and the
expression of endogenous progesterone receptor B (PR B) despite P4 treatment. These results
suggest that hyper-O-GlcNAcylation, common in obese and diabetic patients, may promote
xiii

tumorigenicity in female cancers and could impair the efficacy of progesterone treatment. OGlcNAcylation has the potential to serve as a biomarker for early diagnosis and could predict
treatment success. O-GlcNAc cycling enzyme inhibitors could prove to be useful tools for
providers when treating cancer patients with metabolic disorders.

xiv

CHAPTER 1
LITERATURE REVIEW AND RESEARCH PROPOSAL
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CHAPTER 1
LITERATURE REVIEW AND RESEARCH PROPOSAL

Glycobiology
There are four major classes of macromolecules that come together to support all living
organisms; nucleic acids, protein, lipids, and carbohydrates. While nucleic acids (transcription)
and proteins (translation) have been the focus of substantial biological research, referred to as the
Central Dogma of Biology, carbohydrates have long been down played as a mere means for
energy storage. Despite the discovery of protein bound glycans in the 19th Century, the
importance of glyco-proteins and glyco-lipids has only recently been realized by the scientific
community (Schachter, 2001). While carbohydrates do serve the purpose of energy storage in
the form of glucose and glycogen, protein glycosylation is considered one of the major forms of
protein post-translational modification, massively contributing to the vast diversity of the
proteome (Love et al., 2010).
Glycans, which are branched chain polysaccharides, can be bound to proteins by
asparagine-linkage (N-linked) or serine/threonine linkage (O-linked). These branched chains are
comprised of 6 different sugar moieties: mannose, GlcNAc, Neu5Gc, Galactose, Sialic Acid, and
Fucose. N-linked and O-linked glycosylation are major structural components of both cell
surface and secreted proteins, and significantly influence their structure and function (Varki et
al., 2009). The biological significance of these structures is highlighted by debilitating glycan
associated diseases (Freeze & Schachter, 2009; Varki et al., 2009). A complete lack of Nglycosylation is fatal, but several genetic defects resulting in partial N-glycan pathway
dysfunction result in extensive disability including severe mental retardation, epilepsy, and
2

failure to thrive (Hudson H. Freeze, n.d.). In recent years, it has become clear that several forms
of Muscular Dystrophy stem from under-glycosylation by O-mannose (Kanagawa & Toda,
2006). While our biological understanding of glycosylation has flourished in the past decades,
there is still much to be learned about a unique form of O-linked glycosylation, β-Nacetylglucosamine (O-GlcNAc).
The history and biochemistry of O-GlcNAcylation
O-GlcNAcylation was first described by Hart, et al. in 1984. Originally investigating the
presence of surface glycans with terminal GlcNAc residues, Hart et al. discovered evidence
suggesting the “-presence of O-glycosidicly linked monosaccharides on many lymphocyte cell
surface proteins (Torres & Hart, 1984). Additionally, they discovered a majority of these
moieties appeared to be intracellular, thus a novel single moiety form of glycosylation was
discovered. In the 34 years since this ground breaking publication, more than 1,400 peer
reviewed papers discussing O-GlcNAc have been produced (Lefebvre & Issad, 2015), and while
many of its important mechanisms have been determined, O-GlcNAcylation and its relationship
to disease is still largely an enigma.
While we know substantially less about O-GlcNAcylation compared to some of its
branched counterparts, it is surprising to note that O-GlcNAcylation is both ubiquitous and
abundant in eukaryotic cells. To date, more than 600 O-GlcNAcylated proteins have been
identified, and more are discovered each day. O-GlcNAcylation is a unique form of
glycosylation in many ways. While glycosylation is generally an extra-cellular protein
modification, O-GlcNAcylation occurs in nearly all intracellular compartments. It is found
mostly within the nuclear and cytoplasmic compartments. Beyond its general abundance, O-

3

GlcNAcylation is remarkable for its highly dynamic nature, akin to phosphorylation as a posttranslational modification (Wells et al., 2002). In contrast to phosphorylation, O-GlcNAc
modification is regulated by just two highly-conserved enzymes. β-N-acetylglucosamine
transferase (O-GlcNAc Transferase, OGT) is one of these enzymes and is responsible for adding
the free form substrate UDP-O-GlcNAc to serine and threonine residues on proteins by betaglycosidic linkage. Conversely, β-N-acetylglucosaminase (O-GlcNAcase, OGA) removes the
modification from proteins (F. V Rao et al., 2006).
O-GlcNAc Transferase is heterotrimeric, consisting of two 110 kDa and one 78 kDa subunits, encoded by the OGT gene, which is located on the X chromosome (Xq13). As mentioned
previously, OGT is highly conserved from worms to humans, and complete inhibition of the
enzyme is lethal (Shafi et al., n.d.). Three isoforms of the enzyme have been identified: a full
length (ncOGT), a short length (sOGT), and a mitochondrial variant (mOGT). OGT is tyrosine
phosphorylated, and is O-GlcNAcylated itself, possibly operating as its own regulator of
expression (Aquino-Gil, Pierce, Perez-Cervera, Zenteno, & Lefebvre, n.d.). Comparatively,
OGA is a hydrolase enzyme encoded for by the Meningioma Expressed Antigen 5 (MGEA5)
gene, located on chromosome 10 (10q24.32) (Comtesse, Maldener, & Meese, 2001). There are 3
known isoforms of OGA; a full length (fOGA), a short length (sOGA), and a variant of OGA
(vOGA) (Alonso, Schimpl, & van Aalten, 2014).
Current tools and techniques for studying O-GlcNAcylation
O-GlcNAcylation is described by glycobiologist, John Hanover, as the dark matter of the
glycobiology field (Bond & Hanover, 2015). For nearly 60 years, O-GlcNAcylation has
influenced cellular functions without first being identified. This modification evaded scientific
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discovery for so long because of its small size and labile nature (Greis & Hart, 1998). For
instance, cells have abundant, intrinsic hydrolases, which can remove O-GlcNAc during protein
purification. Further, unlike charged post-translational modifications or PTMs, such as
phosphorylation, O-GlcNAcylation has no charge and thus does not influence the migration
pattern of a protein during gel electrophoresis. Additionally, the addition of an O-GlcNAc
molecule (+203), typically does not impact the apparent molecular mass of a protein, unless there
are many clustered O-GlcNAc modifications. These characteristics also make detection by massspectrometry difficult, as O-GlcNAc modifications tend to be lost during ionization; the free OGlcNAc is then overshadowed by abundant peptides (Varki et al., 2009; Zhongping Tan and LaiXi Wang, 2017; Trinidad, et al., 2012).
While O-GlcNAcylation presents many structural and analytical challenges, several
techniques have been developed to overcome these. For example, the development of a
monoclonal antibody for O-GlcNAc modified proteins (CTD 110.6) facilitated the efficient
detection and purification of O-GlcNAcylated proteins (Whelan & Hart, 2006). There are also
several tools for the manipulation of O-GlcNAcylation, such as small molecule inhibitors of
OGA and OGT, cell culture supplementation of glutamine and glucose, small interfering
(siRNA) or short hairpin RNA (shRNA), and now CRISPR/Cas9 (Banerjee, Hart, & Cho, 2013;
Esko & Bertozzi, 2009; E. J. Kim, Bond, Love, & Hanover, 2014).
Pharmacological inhibitors of OGA exist, N-Acetylglucosaminono-1,5-lactone O(phenylcarbamoyl)oxime (PUGNAc) (Horsch, Hoesch, Vasella, & Rast, 1991), and Thiamet-G
(Yuzwa et al., 2012) are those most notable. The OGA inhibitors PUGNAc has been widely
used to induce a state of hyper-O-GlcNAcylation in a variety of cell types and cell culture
systems (Ali Mehdy, Willy Morelle, Claire Rosnoblet, Dominique Legrand, Tony Lefebvre,
5

2011; Seung Yoon Park, Ryu, & Lee, 2005; Vosseller, Wells, Lane, & Hart, 2002). While both
OGA inhibitors are effective, Thiamet-G has been identified as the more specific inhibitor as it
has higher Ki value for OGA than PUGNAc, and is a more stable bioactive inhibitor of OGA
(Banerjee et al., 2013; Yuzwa et al., 2008).
On the other hand, the development of reliable OGT inhibitors has been extremely
difficult. For instance the drug Alloxan, often used to induce diabetes in mice (Moley, Pellicer,
& Decherney, n.d.), also has OGT inhibitory effects (Konrad et al., 2002). However, Alloxan
was known to be cytotoxic and has many off target effects beyond the inhibition of OGT, such as
the “formation of the reactive oxygen species (ROS) superoxide anions (O2−), hydroxyl radical
(OH·) and hydrogen peroxide (H2O2), causing cell damage through a number of complex

interactions probably involving several different cellular structures” (Zhang, Gao, & Brunk,
1992), and for this reason is not considered a suitable OGT inhibitor. After this, Ac4-5S-GlcNAc
and BADGP, mimics of the OGT donor substrate UDP-GlcNAc were used, however they caused
indirect inhibition of other glycotransferases, impacting cell surface glycan expression (Liu et al.,
2017). In the interim, the chemotherapeutic drug, 6-Diazo-5-oxo-L-norleucine (DON) (Henry
W. Dion, Salvatore A. Fusari, Zbigniew L. Jakubowski & Bartz, 1956) has some indirect
potential. This drug suppresses the presence of UDP-GlcNAc by inhibiting the enzyme
glutamine: fructose-6-phosphate-amido- transferase-1 (GFAT-1). The inhibition of GFAT-1, in
turn, limits the catalytic ability of the Hexosamine Biosynthesis Pathway (HBP), of which the
end product is the OGT substrate, UDP-GlcNAc (Marshall, Bacote, & Traxinger, 1991). More
recently, the Walker laboratory at Harvard developed a small molecule inhibitor of OGT, OSMI1, which effectively inhibits O-GlcNAcylation without impacting transmembrane protein
glycosylation (Ortiz-Meoz et al., 2015). Around this same time, similar inhibitors were also
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introduced to the market in the form of various small molecule and bi-substrate inhibitors (E. J.
Kim et al., 2014; Trapannone, Rafie, & Van Aalten, 2016).
While pharmacological manipulation is an important tool for preliminary research, these
small molecule inhibitors can have unintended consequences. Thus, molecular tools have
become critical for advancing our knowledge. This includes the use of small interfering RNAs
(siRNAs) and short hairpin RNAs (shRNA) to disrupt transcriptional/translational events (D. D.
Rao, Vorhies, Senzer, & Nemunaitis, 2009), or for specific site knockout, point mutations
(Butkinaree et al., 2008). Several studies have been published utilizing point mutation
technology to eliminate an O-GlcNAc binding site of interest. In this technique, minor point
mutations are made at the DNA or RNA level to result in the substitution of a neutral amino acid
residue (typically alanine (Ala)) for a serine or threonine glycosylation site. In example, when OGlcNAcylated serine 30, 31, and 49 of K8/18 filaments are replaced by alanine residues in
transgenic mice, the non-glycosylated mutant mice are more susceptible to liver and pancreatic
injury/apoptosis compared to wild-type mice. The loss of O-GlcNAc resulted in inactivation and
reduced phosphorylation of Akt1 and Protein Kinase Cθ, suggesting that O-GlcNAcylation
supports the phosphorylation of cell-survival kinases (N.-O. Ku, Toivola, Strnad, & Omary,
2010).
Cellular effects of O-GlcNAcylation
Because O-GlcNAc and O-phosphate both modify threonine and serine residues, they
frequently compete with each other for binding. In fact, in many instances, O-GlcNAcylation
inhibits phosphorylation (Hart, Slawson, Ramirez-Correa, & Lagerlof, 2011). One mechanism to
explain this phenomenon is the observation that OGT forms complexes with some phosphatases
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(Chen et al., 2008; Wells, Kreppel, Comer, Wadzinski, & Hart, 2004), which presumably
activates them and then cleaves phosphates from the targeted proteins. Inhibition can also be
attained through direct competition of shared binding sites or steric hindrance in adjacent
residues (Z. Wang et al., 2010). Additionally, instances have been noted where the presence of
an O-GlcNAc moiety on one residue of a protein can impair phosphorylation at a distant site
(Comer & Hart, 2000). One example of this is the cytoskeletal intermediate filament component
keratin 18 (Tao et al., 2006), however the mechanism of inhibition is still unclear.
O-GlcNAcylation has a diverse set of cellular functions in that it can control protein
stability (Sang Yoon Park et al., 2010; Srikanth, Vaidya, & Kalraiya, 2010a; Yuzwa et al., 2012),
influence enzymatic activity, and affect protein-protein interactions, including
transcription/translation (Hardivillé & Hart, 2014; Tarik Issad & Kuo, 2008), cell structure
(Rotty, Hart, & Coulombe, 2010), cell cycle regulation (Jiang et al., 2016; Phie Tan, Duncan, &
Slawson, n.d.) and perhaps most notably, metabolism (Jóźwiak, Forma, Bryś, & Krześlak,
2014a). The novelty of O-GlcNAcylation as a sentinel to cellular metabolism is the origin of its
nucleotide sugar substrate, UDP-GlcNAc. UDP-GlcNAc is the end-product of the Hexosamine
Biosynthesis Pathway (HBP). Approximately 2-5% of all glucose that enters the cell is shuttled
into the HBP by the addition of glutamine to Frustose-6-Phosphate. Further, the fatty acid,
Acetyl-CoA and the nucleotide, Uridine Tri-Phosphate (UTP) pathways converge to be
incorporated into UDP-GlcNAc (Frank, 2012). Thus, the direct link of the HBP to glycolysis and
the amino acid, fatty acid, and nucleotide metabolic pathways make O-GlcNAcylation the ideal
nutrient-sensing modification. As such, the occurrence of hyper-O-GlcNAcylation is associated
with the development of insulin resistance (IR) (Vosseller et al., 2002) and is a characteristic of
Type 2 Diabetes (T2D) and many of its comorbidities (J. Ma & Hart, 2013). Today, many
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scientists consider the development of IR as an adaptive mechanism to protect cells when
nutrients, such as glucose and lipids, are too abundant.
In light of the above observations, it is hypothesized that a high prevalence of OGlcNAcylation in cells provides the trigger for an IR response. Indeed, experimental
overexpression of OGT, which in turn leads to hyper-O-GlcNAcylation, triggers IR in mice
(Yang et al., 2008). Moreover, many of the effects of O-GlcNAc on intracellular signaling are
attributed to the large number of transcription factors that are O-GlcNAcylated, which ultimately
influence gene expression (Tarik Issad & Kuo, 2008).
Diabetes mellitus (DM) is a group of metabolic diseases characterized by
hyperglycemia. Type 1 Diabetes (T1D) stems from the failure of the pancreas to produce
sufficient insulin, the peptide hormone that promotes the absorption of glucose in the cell. Type
2 Diabetes (T2D) is the failure of cells to respond properly to the insulin that is being produced,
known as insulin resistance (IR), which in addition to hyperglycemia can cause
hyperinsulinemia. Although the mechanisms which lead to development of T1D remain unclear,
several risk factors linked to the onset of T2D have been identified. These include the modifiable
risk factors of overweight, unhealthy diet, and physical inactivity. These same risk factors also
lead to an increased flux of glucose into the HBP, prompting the global hyper-O-GlcNAcylation
of proteins (C. Slawson, Copeland, & Hart, 2010). For instance, a recent study showed that
consumption of a Western diet (high in saturated fats and carbohydrates) led to increased OGlcNAcylation in rats (Medford, Chatham, & Marsh, 2012). Increases in O-GlcNAcylation
(hyper-O-GlcNAcylation) are directly linked to insulin resistance and hyperglycemia-induced
glucose toxicity (McClain, 2002). Moreover, there are several proposed mechanisms for the link
between T2D and O-GlcNAcylation. The current working model proposes O-GlcNAc to be a
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nutrient sensing “master switch” that attenuates cellular responses to extracellular stimuli, such
as the metabolic state. In this case, excess glucose within the cell results in an accumulation of
fructose-6-phosphate, which then is shunted to the HBP, causing increased O-GlcNAcylation.
The effect establishes a negative feedback loop through the rate limiting enzyme GFAT, which
then reduces the rate of glucose transport in response to insulin stimulation (Ruan, Singh, Li,
Wu, & Yang, 2013).
O-GlcNAcylation and Cancer
Obesity, diabetes, and excess nutrient intake increase one’s risk for developing several
types of cancer (Calle & Kaaks, 2004; Zelenko & Gallagher, 2014). For example, metabolic
disorders are linked to an increased risk of cancers of the digestive and women’s reproductive
tracts including pancreas (F. Wang, Herrington, Larsson, & Permert, 2003), liver (Adami et al.,
1996), breast (Larsson, Mantzoros, & Wolk, 2007), colorectal (Meyerhardt et al., 2003), urinary
tract (Xu, Huo, Chen, & Yu, 2017), and female reproductive organs (Byrne et al., 2014; Cantrell
et al., 2010; Shoff & Newcomb, 1998). As such, hyper-O-GlcNAcylation is a frequent harbinger
of these cancers (Z. Ma & Vosseller, 2013). The two most critical nutrients to cell proliferation
and growth in cancer are glucose and glutamine, a phenomenon often described as the Warburg
effect (Tekade & Sun, 2017). In the 1960’s Otto Warburg discovered that cancer cells, in
comparison to their normal counterparts, more heavily depended upon anaerobic metabolism,
rather tradition aerobic metabolism, for proliferation and growth even when oxygen is present. In
the average cell, glucose is metabolized to pyruvate, and then enters the Kreb Cycle in the
mitochondria, where the majority of the energy for the cell is generated through oxidative
metabolism. In cancer cells, conversely, glucose is still metabolized to pyruvate, but instead of
undergoing oxidative metabolism, it is converted to lactic acid and secreted by the cell. This less
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efficient form of metabolism is nevertheless viewed as a resourceful mechanism to enable the
rapidly proliferating cancer cells to meet ongoing demands for anabolism of macromolecules
(Heiden et al., 2009). In this context, the shift in metabolism of cancer cells has become a focal
point for the development of new chemotherapeutic drugs.
The nutrient sensing characteristics of OGT link the HBP to oncogenic signaling and
subsequent regulation of glucose and lipid metabolism. Additionally, metabolic reprogramming
in cancer cells is connected to epigenetic changes, including effects of O-GlcNAcylation on
histone modification and regulation of transcription factors (Singh, Zhang, Wu, & Yang, 2015).
For example, Hypoxia-Induced Factor (HIF-1) mediates the cell’s response to reduced O2
availability. Under hypoxic conditions, HIF-1 binds to the hypoxia response element of genes
encoding for glucose transporters (GLUT 1 and 3) and most glycolytic enzymes activating their
transcription (J. Kim, Tchernyshyov, Semenza, & Dang, 2006). O-GlcNAcylation stabilizes HIF1 and results in metabolic reprogramming in cancer cells, and high levels of HIF-1 are associated
with elevated levels of OGT (Ferrer et al., 2014).
In addition to promoting cell proliferation, O-GlcNAcylation also increases migration
and invasion of some types of cancer. For example, O-GlcNAcylation supports a fibroblast-like
phenotype in a colorectal cancer cell line, and silencing of OGA affected the expression of genes
associated with migration and growth (Chaiyawat, Netsirisawan, Svasti, & Champattanachai,
2014). In the lung cancer cell line A549, transformation of cells to a more invasive phenotype
was directly associated with activation of the HBP (Lucena et al., 2016). For cancer cells to
metastasize from a primary tumor site, the cells undergo a transformation. This transformation is
referred to as the epithelial-mesenchymal transition (EMT) because polarized epithelial cells,
bound to the basement membrane, undergo biochemical and morphological transitions to become
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more “mesenchymal like” in their phenotype. Mesenchymal cells have an increased ability to
migrate and invade other tissues, are more resistant to apoptosis than epithelial cells, and have
increased expression of extra cellular matrix (ECM) proteins (Kalluri & Weinberg, 2009). One
key feature of EMT is the notable switch of E-Cadherin vs. N-Cadherin protein expression, in
which cells reduce the expression of the epithelial adhesion molecule, E-Cadherin, in favor of the
expression of the mesenchymal adhesion molecule, N-Cadherin. The reduction in E-Cadherin
expression is largely regulated by the transcription factor, Snail1, which is stabilized by OGlcNAcylation during hyperglycemic conditions (Sang Yoon Park et al., 2010). Additionally,
the HBP is closely connected with several other pathways relevant to the EMT process,
including Wnt (Wu et al., 2014; Zhou et al., 2016) and NOTCH (Taparra, Tran, & Zachara,
2016).
Importantly, O-GlcNAcylation influences many cancers of the female reproductive
system. O-GlcNAcylation and OGT are both regularly elevated in breast and ovarian cancer
(Trinca & Hagan, 2017), and both O-GlcNAc cycling enzymes are elevated in the leading edge
of invasive endometrial tumors (Krześlak, Wójcik-Krowiranda, Forma, Bieńkiewicz, & Bryś,
2012). In cervical cancer, O-GlcNAcylation has been shown to support tumorigenicity through
the HPV genes E6 and E7 (M. Kim et al., 2016). Among these examples, endometrial cancer is
the most common cancer of the female reproductive tract. Women with Type 2 Diabetes (T2D)
have a 2-3 fold increased risk for developing endometrial cancer compared to a metabolically
healthy cohort (Friberg, Orsini, Mantzoros, & Wolk, 2007). This connection provides the
motivation for studies of O-GlcNAc in models of endometrial cancer; however, the literature is
wanting. Among the first few studies to make a connection between O-GlcNAc and endometrial
cancer, in 2012 Krzeslak et al. found that O-GlcNAc cycling enzyme genes (OGT and MGEA5)
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are upregulated along the myometrial-invading edge of endometrial tumors, suggesting a role for
O-GlcNAcylation in metastasis (Krześlak et al., 2012). This discovery supported earlier work
that noted a variation in the extent of O-GlcNAcylation between histological samples of nonpathologic and pathologic endometrium as evaluated immunohistochemically (Sgantzos et al.,
2007). In 2016, Zhou et. al., determined that high glucose culture conditions impair Wnt
signaling and increase the expression of the mesenchymal marker, β-catenin, in the endometrial
cancer cell lines, AN3CA and HEC-1. Additional experiments using the OGA inhibitor,
PUGNAc, revealed these outcomes resulted from increases in HBP activity and subsequent OGlcNAcylation (Zhou et al., 2016). These observations suggest that O-GlcNAcylation plays a
role in the development and progression of endometrial cancer.
Unlike breast and endometrial cancer, obesity and diabetes are not considered leading
risk factors for cervical cancer. However, the autoimmune disease, T1D evidently does double
the risk for cervical cancer (Zendehdel, 2003). The leading cause of cervical cancer is infection
by the human papilloma virus (HPV). There are more than 100 types of HPV, however, only a
handful of these have been linked to cervical cancer, these are referred to as the high risk (HR)
HPV’s. Most notably HR-HPV 16 and 18 are responsible for nearly 71% of all cervical cancer
cases (Burd, 2003). Interestingly, OGT interacts with the HPV oncogenes E6 and E7 to promote
tumorigenesis (M. Kim et al., 2016). Specifically, O-GlcNAcylation, and the expression of OGT
and O-GlcNAcylated HCF-1 are all elevated in cervical cancers, which in turn promotes the
transcription of E6/E7 oncogenes (M. Kim et al., 2016). A similar study corroborated these
observations and also demonstrated that HPV E6 alone induces elevated O-GlcNAcylation (Zeng
et al., 2016). While metabolism does not directly influence the risk of cervical cancer, changes in
O-GlcNAcylation still have a significant impact on cell function and disease progression.
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While insight into the role O-GlcNAcylation in the development and advancement of
cancer has been attained in recent years, the field is still relatively new, and many questions
remain unanswered, especially as they pertain to women’s cancers. The following chapters are
dedicated to new discovery of the impact O-GlcNAcylation on the tumorigenic and metastatic
potential of cervical and endometrial cancer. As is evident from the most current literature, these
areas of cancer biology represent a new frontier that has not been previously explored.

The Potential Link Between Dysregulation of O-linked β-N-acetylglucosamine (O-GlcNAc)
Cycling And Tumorigenicity of Cancers of the Female Reproductive Tract

Diabetes Mellitus is a major risk factor for cancer and continues to be a disease becoming
more prevalent in today’s society. For instance, in 2012 there were 29.1 million Americans
diagnosed with DM; with 1.4 million new cases diagnosed each year (Gallagher & LeRoith,
2015). Of these cases, a shocking 208,000 patients were under the age of 20 (McCarthy, 2014).
As DM affects more people and a higher percentage of youth, it is important that work continue
toward understanding the mechanisms controlling this disease and its associated complications.
In particular, DM associated with both cervical and endometrial cancer threatens the fertility of
the next generation of reproductive-age individuals (Vrachnis et al., 2016). To date, the most
effective, yet least desirable, form of treatment for these cancers is surgery; and while hormonal
treatment is a fertility-sparing option (Kesterson & Fanning, 2012; Montz, Bristow, Bovicelli,
Tomacruz, & Kurman, 2002), the possibility exists that diabetic complications may impact its
effectiveness. Thus, an overarching goal of this study is to determine whether O-GlcNAc status
and its manipulations affect the aggressiveness of cervical and endometrial cancers and how
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hyper-O-GlcNAcylation may pre-dispose cells to metastasis. Additionally, the question of how
high levels of O-GlcNAcylation impact the effectiveness of progesterone treatment will be
explored. Collectively, the work will provide insight about the mechanisms of metastasis in
cancers of the female reproductive tract, which may in turn inform treatment protocols.
Additionally, in the future, O-GlcNAcylation may serve as a biomarker for prognosis and
treatment success, particularly in the context of individualized medicine in which coupling of
dietary or metabolic treatment with current hormone-based methods may be beneficial to at-risk
patients.
Aims and Hypotheses
Aim 1. Determine the effect of global O-GlcNAcylation on tumorigenic potential in cervical
cancer (SiHa) cells.
H1: Global O-GlcNAcylation supports proliferation of cervical cancer cells.
H2: Global O-GlcNAcylation augments migration and invasion of cervical cancer cells.
H3: Reduced O-GlcNAcylation increases susceptibility to cell-mediated death and alters
the cytoskeleton.
Aim 2. Characterize the relationship between O-GlcNAcylation and EpithelialMesenchymal Transition (EMT) in endometrial cancer.
H1: Hyper-O-GlcNAcylation enhances the expression of EMT associated proteins.
H2: Hyper-O-GlcNAcylation stimulates cancer cell proliferation, migration, and
invasion.
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Aim 3. Determine the impact of Global Hyper-O-GlcNAcylation on the efficacy of
progesterone treatment of endometrial cancer.
H1: Hyper-O-GlcNAcylation impairs the anti-proliferative effects of progesterone
treatment.
H2: Hyper-O-GlcNAcylation reverses the anti-invasive effects of progesterone treatment.
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CHAPTER 2
ALLOXAN INDUCED HYPO-O-GLCNACYLATION IMPAIRS CERVICAL CANCER
CELL PROLIFERATION, INVASION, AND CYTOSKELETAL ORGANIZATION

Introduction
Cervical cancer is among the most common types of cancer world-wide, and is the most
readily diagnosed form of cancer for women in developing countries (Vaccarella & Bray, 2015).
Infection by human papillomavirus (HPV) is the primary cause of cervical cancer, with
approximately 97% of all cervical cancer patients testing positive for HPV DNA (Munoz N,
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003). Fifteen types of HPV are
classified as high-risk (HR-HPV) based upon their prevalence and oncogenic nature (Munoz N,
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003), with two types (HPV 16 and 18)
being closely related and contributing to the majority of all cervical cancer tumors (Crow, 2012).
In less-developed nations, cervical cancer continues to be the leading cause of cancer-related
death in women (Crow, 2012; Woodman, Collins, & Young, 2007). Prophylactic measures to
prevent cervical cancer in these parts of the world present logistical challenges, so there is
increasing urgency to gain insight about disease progression and to develop therapeutic methods
that will ultimately eliminate the problem.
In many epithelial cancers, there is an increase in the post-translational modification of
cellular proteins that includes β-N-acetylglucosaminylation (O-GlcNAcylation) (Fardini,
Dehennaut, Lefebvre, & Issad, 2013; Ferrer, Sodi, & Reginato, 2016; Chad Slawson & Hart,
2011). O-GlcNAcylation is a unique form of glycosylation that results in the addition of a single
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sugar moiety, β-N-acetylglucosamine (GlcNAc), to proteins at serine and threonine residues. The
enzyme, O-GlcNAc Transferase (OGT) adds O-GlcNAc to the proteins via the substrate UDPGlcNAc, the end product of the Hexosamine Biosynthesis Pathway (HBSP). Conversely, the
enzyme O-GlcNAcase (OGA) removes O-GlcNAc from the targeted proteins (Bond & Hanover,
2015). In this manner, the reversible and dynamic nature of O-GlcNAc modification is akin to
phosphorylation of cellular proteins rather than simply glycosylation. Because O-GlcNAcylation
occurs on serine and threonine residues it is also known to dynamically influence Ophosphorylation (Comer & Hart, 2000). Proteins can be reciprocally modified by O-GlcNAc and
O-phosphate (i.e., estrogen receptor β) (Cheng & Hart, 2000), while in other instances OGlcNAc physiologically competes with phosphorylation via steric hindrance (Ngoh, Facundo,
Zafir, & Jones, 2010). Still other proteins, for example many cytokeratin intermediate filaments,
exhibit both forms of modifications, but at distant sites (Hart et al., 2011).
The primary cytokeratin heterodimer expressed in most simple epithelial cells is
cytokeratin 8/18. The type I monomer, cytokeratin 18 (K18), is O-GlcNAcylated at three serine
residues in the head domain, while still highly-phosphorylated in the tail domain (N.-O. Ku et al.,
2010; Omary, Ku, Tao, Toivola, & Liao, 2006). The major biological function of cytokeratin is
structural, but K18 is also important in many cellular functions including apoptosis, mitosis, cell
cycle progression, and cell signaling (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo
Sakamoto, PhD, Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010; Pan,
Hobbs, & Coulombe, 2013; Yu-Rong Weng et al., 2012). Additionally, K18 is widely-used as a
diagnostic tool and biomarker for many epithelial cancers (Fortier, Asselin, & Cadrin, 2013a;
Toivola, Boor, Alam, & Strnad, 2015; Yu-Rong Weng et al., 2012), and is known to promote
metastasis (Fortier et al., 2013a). Critically, the dynamic equilibrium of K8/18 filament stability
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between soluble and filamentous forms is crucial in determining cellular function, and is
regulated by both site specific phosphorylation and O-GlcNAcylation (Srikanth, Vaidya, &
Kalraiya, 2010b).
Acknowledging that high intracellular concentrations of O-GlcNAc and high levels of OGlcNAcylation are common among many cancers, the role of this form of glycosylation in
disease progression remains poorly understood. There are a variety of endpoints to measure
metastatic potential, but the extent to which O-GlcNAcylation impacts these measures in cervical
cancer is in its infancy. In the current study we investigated the impact of global OGlcNAcylation on cervical cancer cells, hypothesizing that it augments metastatic potential, in
part by facilitating cytoskeletal re-organization.
Materials and Methods
Cell Culture and Reagents. The human cervical cancer cell line, SiHa (ATCC® HTB35™),
derived from the cervical tumor of a HR-HPV 16-infected patient was used (Friedl, Kimura,
Osato, & Ito, 1970). At present, there are no reports indicating the state of O-GlcNAcylation or
other forms of glycosylation within this cell line. The SiHa cells were maintained in Eagle’s
Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and
antibiotic-antimycotic purchased from Thermo Scientific (Waltham, MA) and cultured in a
humidified 5% CO2 environment at 37°C. Achieving a relative state of hypo-O-GlcNAcylation
was accomplished by exposing the cultures to the OGT inhibitor, Alloxan monohydrate (Konrad
et al., 2002) (5mM) purchased from Sigma-Aldrich (St. Louis, MO) dissolved in DMSO
(Thermo Fisher, Waltham, MA), for a period of 8-24 hours depending upon experimental
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endpoints. Additional SiHa cultures were exposed to an equivalent amount of DMSO (1μl/ml)
as a negative control.
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in flat-sided
Thermo Scientific™ Nunc™ Cell Culture Tubes (Waltham, MA) at an initial seeding density of
50k cells/ml of culture medium as described above. Treatment groups included cultures
continuously exposed to vehicle (DMSO-Control) or 5mM Alloxan. The conditioned culture
medium was exchanged daily, and the cells from one tube for each group were harvested for
counting at 24-hour intervals for a total of seven days.
Caspase-Glo 3/7 Assay for Apoptosis. In a set of 3 independent experiments, cells were seeded
into 96-well plates (Corning™ Costar™ 96-Well White Clear-Bottom Plates) at a density of
20,000 per well in 100μL of complete media, as described above, for 24 hours. Conditioned
medium was then exchanged with fresh medium, now containing 1% FBS, and without/with
Alloxan (5mM) for 8hrs. The cells were then pre-treated for one hour with the protein synthesis
inhibitor, 30µg/ml Cycloheximide (CHX; Sigma-Aldrich), followed by a 10µl spike of either
10µg/ml TNF-alpha (R&D Systems), 1µg/ml Fas-L antibody (CH11; EMD Millipore), or 10µM
Staurosporine (Sigma-Aldrich) for 7.5 hours. Incidence of apoptosis was determined by
measuring caspase activity according to the manufacturer’s recommendations (Caspase-glo 3/7
Assay; Promega, Madison, WI).
Cell Migration Invasion Assay. Three independent in vitro cell migration-invasion
experiments were conducted to measure metastatic potential of the SiHa cells as described in
similar experiments (Hu & Verkman, 2006; Kramer et al., 2013; Qian et al., 2012). Briefly, the
assays were conducted using Corning® Transwell® polycarbonate membrane cell culture inserts
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for 12 well plates (VWR, Radnor, PA) containing a Tissue Culture-treated polycarbonate
membrane filter (6.5mm diameter, 8μm pore size). The upper chamber of each well contained
the SiHa cell suspension (50K cells/well) in serum-free medium, and the lower chamber
contained medium supplemented without/with 10% FBS (chemoattractant). After 6, 12, and 24
hours of incubation at 37°C and 5% CO2, the cells on the top of the membrane (non-invasive)
were removed with a cotton swab, and the inserts were fixed and stained with 250μls of crystal
violet (Thermo Scientific, Waltham, MA). Invasive cells were photographed (200X
magnification) and quantified for 3 random fields (200X magnification) per insert. Relative
migration was calculated by dividing the average number of cells/field by the area of the
microscope viewing field (0.011cm2) and then multiply this number by the entire area of the
Transwell insert (0.3 cm2). Percent invasive was then calculated by dividing this by the number
of cells initially seeded in the inserts (50k cells) as described in the manufacturer’s protocol.
Migration Wound Healing Assay. To confirm and complement the results of the migrationinvasion assay, an in vitro wound healing assay was used to assess metastatic potential of the
SiHa cells, as described for other types of metastatic cells in the literature (Hu & Verkman, 2006;
Kramer et al., 2013; Moy et al., 2014). In a set of three independent experiments, cells were
cultured to confluency in 24 well plates (Thermo Fisher) as described above. The monolayers of
cells were then washed twice to remove non-adherent cells, and “wounded” using a small cell
scraper (Thermo Fisher, cat# 08-100-241) to induce a linear, 4mm-wide wound. The culture
medium was exchanged every 24 hours and Alloxan treatment was maintained throughout the
experiment. At 24 hour intervals, the cells were fixed and stained with crystal violet, and
photographed. Closure of the wound was calculated as a percentage of the total open area and
cell migration rate was calculated as area closed divided by time.
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Immunofluorescent Staining. The effect of global O-GlcNAcylation on the stability of K8/18
filaments in SiHa cells was evaluated immunocytochemically. Briefly, SiHa cells were grown
on 0.1N HCl-treated coverslips for 24 hours and then treated without/with Alloxan for 8hrs. The
cells were washed three times with washing buffer (PBS with 0.1% BSA) and sequentially fixed
for 10 minutes using 100% ice-cold methanol for 10 minutes and blocked for 24 hours with 10%
normal goat serum in 0.1% BSA and phosphate buffered saline. Cells were then incubated for
24 hours at 4°C in primary antibody (anti-human keratin 18 monoclonal antibody, clone CY90,
1:500 dilution; Sigma, St. Lois, MO). Following primary incubation, the cells were then washed
with washing buffer and incubated for one hour at room temperature in detection antibody
(rabbit anti-mouse IgG conjugated with Alexa-488, 1:1000 dilution; Life Technologies, St. Lois,
MO). The cells were counterstained and mounted to slides using ProLong Gold Antifade
Mountant with DAPI (Thermo Fisher), and then imaged using a Zeiss Axiophot microscope
(63X).
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Figure 1: Cell proliferation was impaired by the loss of O-GlcNAcylation (Alloxan) (p<0.0001).
Total number of generations, multiplication rate, and generation time for Control versus OGlcNAc-inhibited cells was 2.2 vs. 0.6 generations, 0.4 vs. 0.1 doublings per day, and 2.35 vs.
7.8 days, respectively for 3 independent experiments.
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Figure 2: [A] Representative images of cell migration from three independent migration
invasion experiments. [B] Percent migration was calculated by dividing the invasive population
(determined by counting 3 random fields) by the number of cells seeded. Invasion was impaired
at 24 hours following hypo-O-GlcNAcylation (Alloxan; P<0.05).
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Figure 3: Representative images of cell migration from three independent wound healing assays.
Inhibition of O-GlcNAcylation reduced the migration rate (P<0.001), and thus the wound healing
potential of the SiHa cells. The migrated surface area and migration rate for control vs. OGlcNAcylation inhibited (Alloxan-treated) cells was 5.5 vs. 4.1 mm2, and 5.5 vs. 4.1μm/hour
respectively. Full wound closure was achieved in control cultures by 120 hours, whereas OGlcNAcylation inhibited cultures did not reach 100% confluency until 168 hours.
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Figure 5: Both control cells (vehicle) and hypo-O-GlcNAcylated (ALX) cells responded to
cytokine treatment (P<0.05). However, reduced O-GlcNAcylation increased SiHa cells
susceptibility to FasL (P<0.01).
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Discussion
Hypo-O-GlcNAcylation impairs cervical cancer cell proliferation, invasion, and migration
Studies of the similar cervical cancer cell line (HeLa), have shown defects in G1
progression following treatment with the GFAT1 inhibitor, DON, to reduce global OGlcNAcylation (Chad Slawson et al., 2005). However, the same study also found increased OGlcNAcylation to cause changes to the cell cycle, possibly through the induced changes to OGT
and OGA expression. Low glucose conditions were also found to down-regulate Sp1 activity
through hyper-O-GlcNAcylation as opposed to hypo-O-GlcNAcylation in the same cell line
(Kang, Ju, Cho, & Hwang, 2003). More consistently, hyper-O-GlcNAcylation has been
implicated in increased proliferation in both breast (Chaiyawat et al., 2014) and ovarian cancer
(Kwei, Baker, & Pelham, 2012). These findings illuminate the complex nature of OGlcNAcylation and highlight its role as nutrient sensor, but do not address the effects of OGT
inhibition, directly. And with recent scrutiny of the reliability of the HeLa cell as a model for
cervical cancer, we felt repeating proliferation studies in a new cell line to be of importance.
SiHa cell proliferation was assessed monitoring growth curves through the death phase in
control cultures (~120 hours; Figure 1). The lack of O-GlcNAcylation (Hypo-O-GlcNAc)
impaired SiHa cell proliferation (p<0.0001) compared to control cultures over the entire length
of the experiment. SiHa cells in control cultures grew an average of 2.2 (+/- 0.96) generations
with an average generation time of 2.5 (+/- 0.12) days (Figure 1). Conversely, Hypo-OGlcNAcylated SiHa cells did not double at all in culture and the generation time extended
beyond the seven days of the experiment. Overall, the doubling rate for controls was four-fold
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higher per day than the Hypo-O-GlcNAcylated cultures (0.4 vs 0.1; p<0.0001) when averaged
across the experiment. Notably, while proliferation rate was significantly impaired by the loss of
O-GlcNAcylation, viability of the SiHa cells was unaffected; viability in both treatment groups
was ~95% as determined by Trypan blue exclusion (results not shown). These results implicate
O-GlcNAcylation as an important regulator of the cell cycle, as concluded in the above
mentioned studies. More specifically, inhibition of OGT has a negative effect on proliferation,
and future studies should focus on the mechanisms responsible.
Observing that O-GlcNAcylation impaired cell proliferation but not viability, we then
investigated the effect of this post-translational modification on aspects of cellular metastasis of
SiHa cells by measuring relative invasiveness and migration potential. Both global and specific
protein and transcription factor O-GlcNAcylation has been linked to increased
migration/invasion in both breast (Sa Caldwell et al., 2010; Huang et al., 2013) and ovarian
cancer (F. Jin, Yu, Zhao, Wu, & Yang, 2013). O-GlcNAc cycling enzymes are also known to be
up-regulated in the myometrial invasive cells of endometrial cancer (Krześlak et al., 2012). In
this way, our findings are consistent with the literature in similar tissue types. Control cultures of
SiHa cells displayed an aggressive phenotype, characterized by cell penetration through the
Transwell® polycarbonate membrane insert within 6 hours of culture (Figure 2). The extent of
cell penetration increased linearly over the next 12 hours and then plateaued at 24 hours (Figure
2B). For purposes of comparison, the 24 hour endpoint was selected to further evaluate SiHa
cell invasiveness in Control and Hypo-O-GlcNAc cultures for this study. Hypo-OGlcNAcylation reduced cell invasion compared to controls as depicted in Figure 2 (p<0.05),
suggesting that GlcNAcylation influences the mobility of the cells. A wound-healing assay,
which evaluates cell migration, was conducted to corroborate this. Hypo-O-GlcNAcylation also
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impaired the migration potential of SiHa cells compared to control, as evidenced by a larger
wound area (55mm2 vs. 4.1mm2) for Hypo vs. control, respectively, P<0.001), 48 hours after
wound creation (Figure 3). This inability of Hypo cells to accomplish wound closure extended
beyond 96 hours of culture, wherein only 60% wound closure was achieved at this time point
(Figure 3).
O-GlcNAcylation may stabilize K18 filaments resulting in increased cell survival
Morphological differences were observed between SiHa cells grown under control
conditions and those in which O-GlcNAcylation is impaired. Hypo-O-GlcNAcylated cells
showed a decrease in cytoplasmic area and were more spindle-like in shape compared to
normally glycosylated cells. To further investigate this observation, cells were grown on
coverslips, fixed, and stained for cytokeratin 18 (figure 4), the main cytokeratin expressed in the
cervix. K18 decreased in perinuclear localization and increased in aggregation. Representative
images from 4 independent experiments suggest hypo-O-GlcNAcylated cells exhibit a change in
K18 organization. Control cells exhibited a filamentous K18 network, while those of the hypoO-GlcNAcylated cells were granular, suggesting increased solubility, which is consistent with
findings in human hepatocytes, where K8/18 is the sole intermediate filament (Srikanth et al.,
2010b).
K18 expression has been implicated in cell survival mechanisms in hepatocytes (N.-O.
Ku et al., 2010) and granulosa cells (Trisdale, Schwab, Hou, Davis, & Townson, 2016), and
previous research conducted with HeLa cells indicated K18 filaments were protective against
Fas-mediated apoptosis (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD,
Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010). The current study saw a
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similar increase in susceptibility to FasL in the presence of an OGT inhibitor (figure 5), but no
increase in susceptibility to TNF-α. These results are congruent with studies on hepatocytes that
found disruption of K8/18 filaments by a point mutation resulted in increased susceptibility to
Fas-induced, but not TNF-induced apoptosis (N. O. Ku, Soetikno, & Omary, 2003). This
supports the hypothesis that O-GlcNAcylation stabilizes K18 filaments in cervical cancer cells,
affording cell survival mechanisms.
Conclusion
O-GlcNAcylation of cervical cancer cells augments tumorigenicity by improving cell
proliferation rate, migration and invasion potential. Additionally, a reduction of OGlcNAcylation resulted in increased solubility of cytokeratin 18 and subsequently, an increased
susceptibility to Fas-mediated cell death. This work suggests a connection between expression of
K18 and O-GlcNAcylation levels in several tumorigenic mechanisms of cervical cancer and
warrants further investigation.
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CHAPTER 3
O-GLCNACYLATION ENHANCES THE TUMORIGENIC PROPERTIES OF CERVICAL
CANCER CELLS IN VITRO
Introduction
Cervical cancer is among the most common types of cancer world-wide, and is the most
readily diagnosed form of cancer for women in developing countries (Vaccarella & Bray, 2015).
Infection by human papillomavirus (HPV) is the primary cause of cervical cancer, with
approximately 97% of all cervical cancer patients testing positive for HPV DNA (Munoz N,
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003). Fifteen types of HPV are
classified as high-risk (HR-HPV) based upon their prevalence and oncogenic nature (Munoz N,
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003), with two types (HPV 16 and 18)
being closely related and contributing to the majority of all cervical cancer tumors (Crow, 2012).
In less-developed nations, cervical cancer continues to be the leading cause of cancer-related
death in women (Crow, 2012; Woodman et al., 2007). Prophylactic measures to prevent cervical
cancer in these parts of the world present logistical challenges, so there is increasing urgency to
gain fundamental insight about disease progression and to develop therapeutic methods that will
ultimately eliminate the problem.
In many epithelial cancers, disease onset and progression are associated with increases in
post-translational modification of cellular proteins, including β-N-acetylglucosaminylation (OGlcNAcylation) (Fardini et al., 2013; Z. Ma & Vosseller, 2013; Chad Slawson & Hart, 2011). OGlcNAcylation is a unique form of glycosylation that results in the addition of a single sugar
moiety, β-N-acetylglucosamine (GlcNAc), to proteins at serine and threonine residues. The
enzyme, O-GlcNAc Transferase (OGT) adds O-GlcNAc to the proteins via the substrate UDP33

GlcNAc, the end-product of the hexosamine biosynthesis pathway (HBSP). Conversely, the
enzyme O-GlcNAcase (OGA) removes O-GlcNAc from the targeted proteins (Bond & Hanover,
2015). In this manner, the reversible and dynamic nature of O-GlcNAc modification is akin to
phosphorylation of cellular proteins rather than simply glycosylation. Because O-GlcNAcylation
occurs on serine and threonine residues, it can dynamically influence O-phosphorylation (Comer
& Hart, 2000). Proteins can be reciprocally modified by O-GlcNAc and O-phosphate (e.g.,
estrogen receptor β (Cheng & Hart, 2000)), while in other instances O-GlcNAc competes with
phosphorylation physiologically via steric hindrance (Ngoh et al., 2010). Still other proteins, for
example many cytokeratin intermediate filaments, exhibit both forms of modifications, but at
distant sites (Hart et al., 2011).
The most common type of cytokeratin intermediate filament expressed in simple
epithelial cells is the heterodimer, cytokeratin 8/18 (K8/18). The type I monomer, cytokeratin 18
(K18), is O-GlcNAcylated at three serine residues in the head domain, while still highlyphosphorylated in the tail domain (N.-O. Ku et al., 2010; Omary et al., 2006). The major
biological function of cytokeratins is structural, but K8/18 filaments are also important in many
cellular functions including apoptosis, mitosis, cell cycle progression, and cell signaling (Brian
T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD, Luiz E Henkes, PhD, David H.
Townson, PhD, and Bo Rueda, 2010; Pan et al., 2013; Y.-R. Weng, Cui, & Fang, 2012).
Additionally, K18 of K8/18 filaments is widely-used as a diagnostic tool and biomarker for
many epithelial cancers (Fortier, Asselin, & Cadrin, 2013b; Toivola et al., 2015; Y.-R. Weng et
al., 2012), and is known to promote metastasis (Fortier et al., 2013b). Importantly, the dynamic
equilibrium of K8/18 filament stability between soluble and filamentous forms is crucial in

34

determining cellular function, and this stability is regulated by both site-specific phosphorylation
and O-GlcNAcylation (Srikanth et al., 2010a).
High intracellular concentrations of O-GlcNAc and high levels of O-GlcNAcylation are
common among many cancers, yet the role of this form of glycosylation in disease progression is
less understood. Additionally, there are a variety of endpoints to measure metastatic potential,
but the extent to which O-GlcNAcylation impacts these measures in cervical cancer is unknown.
The objective of the current study was to investigate the impact of global O-GlcNAcylation on
cervical cancer cells, hypothesizing that O-GlcNAcylation augments metastatic potential, in part
by influencing K8/18 filaments and cytoskeletal re-organization.
Materials and Methods
Cell Culture and Reagents. The human cervical cancer cell line, SiHa (ATCC® HTB35™),
derived from the cervical tumor of a HR-HPV 16-infected patient was used (Friedl et al., 1970).
At present, there is no information available indicating the state of O-GlcNAcylation or other
forms of glycosylation within this cell line. For culture, the SiHa cells were maintained in
Eagle’s Minimum Essential Medium (EMEM), supplemented with 10% fetal bovine serum
(FBS) and antibiotic-antimycotic, all purchased from Thermo Fisher Scientific (Waltham, MA).
The cells were incubated in a humidified, 5% CO2 environment at 37°C. Global inhibition of OGlcNAcylation (Hypo- O-GlcNAcylation) was achieved by exposing the cells to the OGT
inhibitor, OSMI-1 (50μM) as described previously by others (M. Kim et al., 2016; Ortiz-Meoz et
al., 2015), and was verified by immunoblotting (described below). The OSMI-1 was purchased
from Aobious (Gloucester, MA) dissolved in DMSO (Thermo Fisher), and the cells were
exposed for a period of 9-24 hours depending upon the experimental endpoint (described below).
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Additional cultures of SiHa cells were exposed to an equivalent amount of DMSO (1μl/ml) as a
negative control.
Immunoblotting for Global O-GlcNAcylation. Whole cell lysates of SiHa cells cultured in
25cm2 flasks (Corning, Corning, NY) for 48 hours, were harvested by scraping, and separated on
pre-stained SDS-Page gels (BioRad, Hercules, CA) and transferred to PVDF membrane.
Membranes were then probed for global O-GlcNAcylation (CST-O-GlcNAc 110.6 antibody;
Cell Signaling Technology, Inc.; Beverly, MA) and then secondary antibody (Anti-rabbit IgG
HRP-linked Antibody, Cell Signaling Technology, Inc.), followed by Clarity Western ECL
substrate (BioRad). Blots were imaged on the BioRad ChemiDoc Imaging System.
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in duplicate
in flat-sided Thermo Fisher Scientific™ Nunc™ Cell Culture Tubes at an initial seeding density
of 60k cells/ml of culture medium. Treatment groups included cultures of cells continuously
exposed to vehicle (DMSO-Control) or 50μM OSMI-1. The conditioned culture medium was
exchanged without/with treatment daily, and the cells for each group were harvested for counting
at 24-hour intervals over a seven-day period.
Flow Cytometric Analysis of Cell Cycle Progression. In a set of 3 independent experiments,
SiHa cells were seeded at a density of 100,000 cells/ml in T-25 flasks (Corning) and treated
without or with OSMI-1 in culture through the exponential growth phase before being
enzymatically harvested and fixed/permeabilized with 70% ethanol. The cells were then stained
with propidium iodide (PI) and fluorescence was measured with a 488nm laser (610/20 BP
Filter) on a BD LSRII Flow Cytometer. Data were analyzed with Flow Jo Analysis Software.
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Caspase-Glo 3/7 Assay for Fas-Induced Apoptosis. In a set of 3 independent experiments,
SiHa cells were seeded in triplicate into 96-well plates (Corning™ Costar™ 96-Well White
Clear-Bottom Plates) at a density of 20,000 per well in 100μL of complete media and then
cultured without or with OSMI-1 (50 µM) for 24 hours. The cells were then pretreated for 30
min with the protein synthesis inhibitor, 30µg/ml Cycloheximide (CHX; Sigma-Aldrich),
followed by 1µg/ml Fas-L antibody (CH11; EMD Millipore), or 10µM Staurosporine (SigmaAldrich) for 8 hours. The incidence of apoptosis was determined using a caspase enzyme assay,
following the manufacturer’s recommendations (Caspase-Glo 3/7 Assay; Promega, Madison,
WI).
Cell Migration Invasion Assay. Three independent in vitro cell migration-invasion experiments
were conducted to measure metastatic potential of the SiHa cells. The assays were conducted
using Corning® Transwell® polycarbonate membrane cell culture inserts for 24 well plates
(VWR, Radnor, PA) containing a Tissue Culture-treated polycarbonate membrane filter (6.5mm
diameter, 8μm pore size). This approach has been described previously by others in similar
experiments (Hu & Verkman, 2006; Kramer et al., 2013; Qian et al., 2012). Briefly, the upper
chamber of each well was seeded with SiHa cells (50K cells/well) in serum-free medium without
or with OSMI-1 (50 µM) and the lower chamber contained medium supplemented without or
with 10% FBS (chemoattractant). Treatments for each experiment were conducted in triplicate.
After 24 hours of incubation at 37°C and 5% CO2, the cells on the top of the membrane (noninvasive) were removed with a cotton swab, and the inserts were fixed and stained with 600μl of
crystal violet (Thermo Scientific). Invasive cells that had penetrated the membrane were
photographed (20X magnification). Invasiveness was also quantified by de-staining the
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membranes in 600ul of 70% ethanol for 10 minutes and then measuring the absorbance at
540nm.
Immunocytochemistry of Cytoskeletal Proteins. SiHa cells were cultured in 12 well plates
(100K cells/well) on glass cover slips using conditions described above for 24 hours, then fixed
and permeabilized with 100% methanol. Primary antibodies for the detection of K18 in the
K8/18 filaments (CY90 antibody, Cell Signaling Technology, Inc.), α-tubulin (236-10501
antibody, Thermo Fisher Scientific, Waltham, MA), and β-actin (13E5 antibody, Cell Signaling
Technology, Inc.) were applied, followed by wash steps and detection using the secondary
antibody (Anti-rabbit or IgG, HRP-linked Antibody, Cell Signaling Technologies) and AEC
substrate kit (Vector Laboratories, Burlingame, CA). The cells were counterstained with
hematoxylin (Vector), mounted onto slides, and imaged at 40X.
Statistical Analysis. All experiments were independently repeated a minimum of three times,
using a fresh aliquot of SiHa cells (passage 4-7) to initiate each experiment. Data were analyzed
by one- or two-way analysis of variance (ANOVA), followed by a Student’s t post-test for
multiple comparisons; differences among means were considered significant at p<0.05.
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Figure 1. Inhibition of global O-GlcNAcylation by OSMI-1. [A] Immunoblot analysis of global
O-GlcNAc in SiHa whole cell lysates following treatment with OSMI-1 for 4 and 24 hours. OGlcNAcylation of cellular proteins declined within 4 hours of OSMI-1 treatment and remained
diminished through 24 hours. There was no effect of OSMI-1 on total protein expression, as
indicated in the lower panel [B] Impaired O-GlcNAcylation was also evident in fixed, cultured
cells, wherein immunostaining for O-GlcNAcylation was reduced throughout the cytoplasm of
OSMI-1 treated cells, 24 hours after treatment (40X magnification). Representative images of 3
independent experiments.
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Figure 2. SiHa cell proliferation is impaired by Hypo-O-GlcNAcylation. [A] SiHa cell
proliferation was impaired (p<0.01) by Hypo-O-GlcNAcylation following OSMI-1 exposure.
Total number of generations, multiplication rate, and generation time for control versus Hypo-OGlcNAcylated cells were all reduced following 3 independent experiments. [B] Flow cytometric
analysis of parameters of cell cycle progression revealed no effect of Hypo-O-GlcNAcylation
when comparing control and OSMI-1 treated cultures.
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Figure 3. Effect of Hypo-O-GlcNAcylation on SiHa cell invasion. [A] Representative images
(10X) depicting SiHa cells that have penetrated the Transwell inserts in response to
chemoattractant.

Note that OSMI-1 treatment impaired cell penetration. [B] A bar graph

comparing the invasiveness of SiHa cells in control and Hypo-O-GlcNAcylated cultures for 3
independent experiments (Mean ±SEM) is shown. Bars with different letters denote differences
(p<0.05).
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Figure 4. Effects of Hypo-O-GlcNAcylation on SiHa cell morphology and cytoskeletal
expression. Representative images (40X) of immunocytochemical staining for keratin 18, αtubulin, and β-actin in SiHa cells are shown. Hypo-O-GlcNAcylation reduced both Keratin 18 and
β-actin expression. There were no obvious alterations of α-tubulin expression observed. These
outcomes were evaluated following three independent experiments.
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Figure 5: Effect of Hypo-O-GlcNAcylation on SiHa cell sensitivity to apoptosis. A bar graph
depicts the relative sensitivity of SiHa cells (Mean ±SEM) to cytokine- (Fas-L) and
chemotherapeutic- (Staurosporine) induced apoptosis (as measured by cleaved caspase 3/7
activity) following three independent experiments. Cytokine in the presence of the protein
synthesis inhibitor, cycloheximide (CHX), induced apoptosis (p<0.05), but impairment of OGlcNAcylation did alter the sensitivity of the cells to FasL. Staurosporine was used as the positive
control for the assay. Bars with different letters denote differences (p<0.05).
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Discussion
Hypo-O-GlcNAcylation of SiHa cells impairs cell proliferation and invasion
A variety of studies have demonstrated that the state of global O-GlcNAcylation in cells,
including epithelial-derived cancer cells, can have profound physiological effects on growth and
development. In the current study, the effect of global O-GlcNAcylation on proliferation,
invasion, and cytoskeletal organization was assessed in a cervical cancer cell line (SiHa cells).
To our knowledge, this is the first report of the effects of the highly-specific O-GlcNAc
Transferase (OGT) inhibitor, OSMI-1, on cervical cancer cells. The ability of OSMI-1 to
globally impair O-GlcNAcylation, without affecting SiHa cell viability, was clearly evident in
these experiments, and was sustained for an extended period (Figure 1). Cell proliferation was
assessed by monitoring growth curves through the death phase, and revealed that the lack of OGlcNAcylation (Hypo-O-GlcNAc) impaired proliferation (p<0.01) over the entire length of the
experiment (Figure 2A). Overall, the doubling rate for controls was more than three-fold higher
per day than the Hypo-O-GlcNAcylated cultures (0.7 vs 0.2; p<0.01) when averaged across the
experiment. These results suggest O-GlcNAcylation regulates mitosis, possibly via the cell cycle
(Chad Slawson et al., 2005). Indeed, others have reported the cell cycle is accelerated (G1S)
following exposure to the GFAT1 inhibitor, DON, which reduces global O-GlcNAcylation (Sa
Caldwell et al., 2010); whereas the same study determined that increased O-GlcNAcylation
delays G2/M progression, possibly through induced changes to OGT and OGA activity. These
findings illuminate the complex, sometimes unpredictable, nature of O-GlcNAcylation in cells.
In the current study, however, hypo-O-GlcNAcylation via OSMI-1 had no effect on parameters
of cell cycle progression (Figure 2B), indicating that SiHa proliferation is impaired in some other
way.
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Observing that hypo-O-GlcNAcylation impaired cell proliferation, but not viability, we
then investigated the effect of this post-translational modification on aspects of cellular
metastasis by evaluating the relative invasiveness of SiHa cells. Both global and specific OGlcNAcylation of proteins and transcription factors are linked to increased cell
invasiveness/migration in breast and ovarian cancers (Huang et al., 2013; F.-Z. Jin, Yu, Zhao,
Wu, & Yang, 2013; Steenackers et al., 2016). Similarly, upregulation of O-GlcNAc enzymes is
associated with myometrial invasive cells in endometrial cancer (Krześlak et al., 2012). Our
results are consistent with these findings. Control cultures of SiHa cells exhibited an aggressive
phenotype, characterized by cell penetration through the Transwell® polycarbonate membrane
insert within 24 hours of culture (Figure 3A). Conversely, hypo-O-GlcNAcylation reduced cell
invasion (p<0.05; Figure 3B), suggesting that O-GlcNAcylation augments the mobility of the
cells. Overall, the results indicate that O-GlcNAcylation, specifically through the actions of
OGT, heightens the tumorigenic potential of cervical cancer cells by accelerating both
proliferation and invasion capabilities. These observations agree with a recent study of OGT
manipulation in colon cancer cell lines, wherein genetic silencing of OGT impaired cell
invasiveness and migration (Steenackers et al., 2016).
Hypo-O-GlcNAcylation affects cytoskeletal morphology, but not Fas-induced apoptosis
Cytoskeletal proteins are fertile targets for post-translational modification, including OGlcNAcylation, so it is plausible for O-GlcNAcylation to affect cell morphology. Indeed, SiHa
cells exhibited pronounced changes in morphology following OSMI-1 treatment compared to
control cells (Figure 4). Notably, immunostaining for K18 and β-actin proteins was diminished
in Hypo-O-GlcNAcylated cells, and the cells generally had a flattened, stellate morphology
compared to the more spindle-like appearance of control cells (Figure 4). For K18, in particular,
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staining was uniformly detectable throughout the cytoplasm in control cells; whereas it remained
primarily perinuclear, and somewhat aggregated as it extended to the periphery in Hypo-OGlcNAcylated cells (Figure 4). Similar forms of filament reorganization have been noted in
other epithelial cancers (Busch et al., n.d.), and are believed to be a direct result of K8
phosphorylation in K8/18 filaments (Fois, Weimer, Busch, & Felder, 2013). In the current study,
there was no evidence that α-tubulin expression was affected by hypo-O-GlycNAcylation
(Figure 4), despite the observation that K18 and β-actin expression were both diminished. Others
have observed that α-tubulin and β-actin expression in colon cancer cells are unaffected by
inhibition of OGT, yet the morphology of these cells is “stocky and stunted” (Steenackers et al.,
2016). Although K8/18 filament expression was not evaluated, the results of the previous study
did support the concept that hypo-O-GlcNAcylation disrupts cytoskeletal organization. Beyond
a structural role, K8/18 filaments also influence cell survival, specifically providing resistance to
Fas-induced apoptosis (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD,
Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010; N.-O. Ku et al., 2010;
Trisdale et al., 2016). In the present study, we found that SiHa cells are indeed resistant to Fasinduced apoptosis, but such resistance is not influenced by hypo-O-GlyNAcylation (Figure 5;
p>0.05), or associated with a loss of K8/18 filament expression (Figure 4). This suggests the
mechanism(s) of Fas-resistance in SiHa cells involve processes other than O-GlyNAcylation and
proteins other than K8/18 filaments. Additionally, as noted above, the overall viability of the
SiHa cells remained unaffected by hypo-O-GlyNAcylation, as measured by caspase 3/7 enzyme
activity (Figure 5; Control vs. Hypo-O-GlycNAcylated, p>0.05). Thus while other
investigations have concluded O-GlcNAcylation is fundamental to cell viability, especially in
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embryonic stem cells (Shafi et al., n.d.), the extent of impairment of O-GlcNAcylation in the
current study was insufficient to hinder cell survival.
Conclusion
Overall, O-GlcNAcylation enhances the tumorigenic properties of SiHa cells by
accelerating cell proliferation and augmenting invasive and migratory capabilities. Conversely,
hypo-O-GlcNAcylation alters cellular morphology and cytoskeletal organization, in part by
reducing the expression of K8/18 and β-actin filament proteins. The results support the
hypothesis that O-GlcNAcylation augments metastatic potential of cervical cancer cells and
suggest there is a physiologic connection between O-GlcNAcylation and cytoskeletal
reorganization, ostensibly involving the modulation of O-phosphorylation of K8/18 filaments,
but this warrants further study.
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CHAPTER 4

HYPER-O-GLCNACYLATION PROMOTES EPITHELIAL-MESENCHYMAL
TRANSITION IN ENDOMETRIAL CANCER CELLS

Introduction
β-N-acetylglucosaminylation (O-GlcNAcylation) is a unique form of glycosylation that
occurs on serine and threonine residues of proteins throughout the cytoplasmic and nuclear
compartment of cells. It is a monosaccharide that is dynamically cycled akin to that of Ophosphorylation. The enzyme O-GlcNAc transferase (OGT) adds O-GlcNAc to proteins via the
substrate UDP-GlcNAc, while O-GlcNAcase (OGA) is responsible for its removal. O-GlcNAc
influences the extent of O-phosphorylation of proteins through shared binding sites and steric
hindrance (Bond & Hanover, 2015). As the end-product of the Hexosamine Biosynthesis
pathway (HBP), UDP-GlcNAc and subsequent O-GlcNAcylation is considered a nutrient sensor
to the overall metabolic status of the cell. Two to five percent of the glucose that enters the cell is
channeled into the HBP. As such, it is not surprising that increased O-GlcNAcylation is
implicated in the development of insulin resistance (T Issad, Masson, & Pagesy, 2010). Aberrant
O-GlcNAcylation is a characteristic of heart disease, neurodegenerative disorders such as
Alzheimer’s disease, and is a hallmark of many cancers, including endometrial cancer (Krześlak
et al., 2012). A relationship between glycosylation and metastasis is also evident in lung cancers,
wherein epithelial-mesenchymal transition (EMT) acts through the HBP as an inducer of
aberrant glycosylation (Lucena et al., 2016). Despite these observations, very little is known
about the mechanistic actions of O-GlcNAcylation in cancer, specifically, in the EMT process.
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Many illnesses associated with aberrant O-GlcNAcylation are also co-morbidities of
Type 2 Diabetes (T2D). For instance, women with T2D have a 2-fold greater risk of developing
endometrial cancer than their healthy cohorts (Friberg et al., 2007). While the incidence of many
forms of cancer is declining, endometrial cancer remains among those increasing for all women
(Cote, Ruterbusch, Olson, Lu, & Ali-Fehmi, 2015). Endometrial cancer results from the
abnormal growth, migration, and invasion of cells that line the uterus. Common genetic
alterations in endometrial tumors include PTEN, PIK3CA, CTNNB1 (beta-catenin), and KRAS,
all of which are related to metabolism (Byrne et al., 2014). Moreover, all of these genes
influence epithelial-mesenchymal transition (EMT) signaling pathways, and recent studies
indicate that the E-cadherin repressors Slug, ZEB1, and HMGA2 are preferentially expressed
along the myometrial invasive edge of tumors (Stewart & Mccluggage, 2013). Snail1, a key
regulator of EMT, is stabilized by O-GlcNAcylation in several cell types (Sang Yoon Park et al.,
2010), and the mRNA of O-GlcNAc cycling enzymes (OGT and OGA) is up-regulated in
endometrial tumors(Krześlak et al., 2012), suggesting that O-GlcNAcylation influences
metastasis.
The gold standard for treatment of endometrial cancer is radiation therapy and surgery;
however, 5-30% of women with endometrial cancer are premenopausal and under the age of 50
at the time of diagnosis. For these women, fertility-sparing treatments, such as progestin therapy,
are an option (Jeong-Yeol Park, 2015). A recent meta-analysis determined that women treated
with hormonal therapy methods had a pooled regression rate of 76.2%, with 28% live births
reported; however, a 40.6% relapse rate was also noted (Gallos et al., 2012). These findings
underscore the importance of identifying basic mechanisms by which metabolism and OGlcNAcylation influence the progression of endometrial cancer, with the goal of improving
50

fertility-sparing treatments. Therefore, the objective of this study was to determine these
mechanisms, specifically focusing on the manipulation of O-GlcNAc cycling enzymes (OGT and
OGA) and the impact on molecular and cellular aspects of Epithelial-Mesenchymal Transition
(EMT).
Materials and Methods
Cell Culture/Reagents. Endometrial Cancer cells (Ishikawa) were obtained from Sigma Aldrich
(cat. #99040201). Cell Line authentication was performed before, during, and after
experimentation in the University of Vermont Cancer Center Advanced Genome Technologies
Core and was supported by the University of Vermont Cancer Center, Lake Champlain Cancer
Research Organization, and the University of Vermont College of Medicine. O-GlcNAcylation
in cells was manipulated by the OGA inhibitor, ThmG (1μM, Fisher Scientific), the OGT
inhibitor, OSMI-1 (50μM, Aobious), and supplementation of excess glucose (25Mm). ThmG and
OSMI-1 were dissolved in DMSO (Fisher Scientific) at a concentration of 1000X, thus control
and glucose treated cells received 0.1% DMSO (vehicle). Cell culture media (EMEM, 10% FBS
and 10μl/mL antibiotic-anti-mycotic (Fisher Scientific) was exchanged every 24 hours unless
otherwise specified.
Immunoblotting. Cell Lysates were harvested via trypsin digestion and dissolved in RIPA
buffer, and then passaged 5 times through a 26G needle. Protein concentration was measured by
BCA Assay (BioRad) following the manufacturer’s protocol. Pre-stained SDS-PAGE gels were
loaded with 20μg of proteins per lane. Protein was then transferred to PVDF membrane
(Millipore). Membranes were then probed with antibodies associated with EMT (EMT antibody
kit), the Akt Pathway (Akt Pathway Antibody Kit), O-GlcNAc (CTD 110.6), OGT, and OGA.
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Goat-anti-rabbit and goat-anti-mouse HRP conjugated secondary antibodies were used in
combination with Clarity Western ECL Clotting Substrate (BioRad) for imaging on the BioRad
ChemiDoc Imager. All antibodies were purchased from Cell Signaling unless otherwise
specified.
Immunohistochemistry. Cells were seeded at 50,000 cells/mL in black-walled 96 wells plates
and incubated in treatments described above, with or without 5ng/mL TGF-β (R&D Systems),
for 72 hours. Media was exchanged daily. Cells were then fixed with 4% paraformaldehyde in
PBS (Fisher Scientific) and stained with Alexaflour-488 Phalloidin (Molecular Probes, Eugene,
OR) and DAPI (Molecular Probes). Cells were imaged with the Olympus CKX53 at 200X.
Proliferation and Migration. A wound-healing assay was used to measure cell proliferation of
Control cells (vehicle, DMSO), Hyper-O-GlcNAcylated cells (25Mm Glucose or 1μM ThmG),
and Hypo-O-GlcNAcylated cells (50μM OSMI-1). Confluent monolayers of treated cells grown
in 24 well plates in EMEM with 10% FBS. “Wounds” were created by running a 200μL pipette
tip across the monolayer. At 0 hours and every 24 hours following, the “wound” area was
measured with ImageJ software and percent wound closure was calculated. Three independent
wound-healing assays were also conducted to assess the migration potential of treated cells.
Confluent monolayers of treated cells grown in 24 well plates were serum starved for 24 hours
before “wounds” were created by running a 200μL pipette tip across the monolayer. Cells were
maintained in serum free conditions to inhibit proliferation and were incubated at 37°C and 5%
CO2 for 18 hours. The “wound” area was measured with ImageJ software at 0 and 18 hours to
calculate percent wound closure.
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Invasion. Corning Matrigel Biocoat Invasion Chambers (24 well, 0.8μ) (Corning, Bedford, MA)
were used to assess the invasion potential of treated cells compared to control. The upper
chamber was seeded with 100,000 serum-starved cells stimulated with 5ng/ml TGF-β. Cells were
exposed to O-GlcNAc-modifying treatments at the time of seeding. The lower chamber
contained 5% FBS as a chemoattractant. Cells were incubated for 48 hours at 37°C and 5% CO2.
Cells were then removed from the upper chamber and the Transwell membranes were fixed with
100% methanol and stained with Crystal Violet. Invaded cells were then counted by two
independent researchers and the results were averaged.
RT PCR Array. RNA was extracted from treated cell pellets with the RNeasy Mini-Kit
(Qiagen) with DNase digestion (RNAse free DNase Kit, QIAGEN) following the manufacturer
protocols. The cDNA synthesis and RT2 Profiler PCR Arrays (QIAGEN, PAHS-090Z) (Supp.
Table 1) were performed in the University of Vermont Cancer Center Advanced Genome
Technologies Core and was supported by the University of Vermont Cancer Center, Lake
Champlain Cancer Research Organization, and the University of Vermont College of Medicine.
Results were analyzed via the GeneGlobe Data Analysis Center (QIAGEN).
Oncogenomic Data Analysis. Multidimensional cancer genomic data analysis was performed
using online data-mining tool from the cBioPortal for Cancer Genomics (http://cbioportal.org)
and the data sets from the cBioPortal for Cancer Genomics and the TCGA research Network
(http://cancergenome.nih.gov) according to recently published protocols.26, 27 Tumor types and
data sets are chosen in accordance with the publication guidelines from TCGA (last update:30
September 2014). Genomic alterations were identified when the following occurred: (1) gene
mutations; (2) putative copy number alteration (amplification or deletion); (3) RNA expression
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Z-scores (RNA Seq Version 2 RSEM) with Z-score thresholds±2.0; and (4) protein/phosphoprotein level (RPPA) with Z-score thresholds±2.0.
Data Analysis. A minimum of 3 independent replicates were completed for each experiment,
reported as mean +/- SEMs. Statistical analysis was conducted using 2-Way ANOVA and
Student’s t-tests with JMP Pro 13 Statistical Analysis Software. Fold-change differences in
mRNA expression were calculated with the GeneGlobe Data Analysis Center (QIAGEN) for
RT2 Profiler PCR Arrays.
Results
The O-GlcNAc cycling enzymes, OGT and OGA, are altered in endometrial cancer
Analysis of gene alterations for OGT and OGA (OGT and MGEA5, respectively) using
data from the RNAseq and Microarray databases available in cBioPortal (cBioPortal.org)
revealed that of the 18 female reproductive cancer databases available, Uterine/Endometrial
Cancer ranks highest for gene alterations to OGT and MGEA5 , including both mutational and
amplification modifications (Figure 1A). Additionally, both genes are upregulated in participants
with Diabetes Mellitus compared to non-Diabetic controls (Figures 1B). These findings are
consistent with the previous assertion that O-GlcNAc enzyme gene expression is increased along
the myometrial invasive edge of endometrial tumors (Krześlak et al., 2012). Similarly, elevated
expression of OGT and MGEA5 mRNA is consistent with the nutrient-sensing nature of OGlcNAcylation. High nutrient intake, hyperglycemia, and other metabolic abnormalities all
promote the flow of glucose into the HBP, resulting in elevated O-GlcNAcylation. In this way,
the current findings of the meta-analysis add support to the concept that O-GlcNAc modification
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has a role in the development of diabetic complications and cancer (Copeland, Han, & Hart,
2013; T Issad et al., 2010; Ruan et al., 2013).
Detection and manipulation of O-GlcNAcylation in the endometrial cancer line, Ishikawa
Immunodetection of global O-GlcNAcylation in Ishikawa cells revealed this form of
protein modification was upregulated (Hyper-O-GlcNAcylation) in cells by supplementing
complete media with 25mM Glucose or by inhibiting OGA with Thiamet-G (1μM; ThmG)
(Figures 1C and 1D), and downregulated (Hypo-GlcNAcylation) by inhibiting OGT with OSMI1 (50μM) (Figures 1C and 1 D). These manipulations of O-GlcNAcylation were then utilized in
all subsequent experiments to determine effects of aberrant O-GlcNAcylation on phenotypic
changes in Ishikawa cells (i.e., cell proliferation/migration and invasion), as well as
morphological and molecular alterations associated with EMT.
Hyper-O-GlcNAcylation supports endometrial cancer cell proliferation/migration, and
promotes invasion
A wound healing assay demonstrated that Hyper-O-GlcNAcylation supported Ishikawa
cell proliferation and migration, with no difference in wound closure observed among Control,
Glucose and ThmG-treated cultures (p>0.05; Figures 2A and B). Hence, Hyper-OGlcNAcylation was conducive to wound closure. Conversely, Hypo-O-GlcNAcylation (via
OSMI-1) impaired cell proliferation/migration (p<0.05), resulting in wounds that failed to close
within the time constraints of the experimental period (~40% wound closure after 72- hours of
culture; Figures 2A and B). The inhibition was serum-dependent, however, as no difference in
wound closure was observed among the treatment groups when FBS was excluded from the
culture medium (p>0.05; Figure 2C).
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Although Ishikawa cells are considered relatively-low metastatic cells (Kaori Ohtani,
Hideki Sakamoto, Thomas Rutherford, Zhaocong Chen, Kazuo Satoh, 1999), treatment with
Hyper-O-GlcNAcylation (ThmG treatment) augmented invasiveness compared to Control and
Hypo-O-GlcNAcylated (OSMI-1-treated) cells (p<0.05; Figures 2D and E). Glucose
supplementation provided an intermediate response, midway between Control and Hyper-OGlcNAcylated cells (Figure 2E). The Hypo-O-GlcNAcylated cells (OSMI-1-treated) exhibited
no invasion potential, comparable to Controls (p>0.05; Figures 2D and E).
Hyper-O-GlcNAcylation promotes the EMT phenotype
The EMT process was examined in Ishikawa cells at both the mRNA and protein levels by
manipulating O-GlcNAc modification (as previously described). Phalloidin staining of stress
filaments in these cells (F-actin) revealed diffuse and epithelial-like staining in Hypo-OGlcNAcylated (OSMI-1- treated) cells (Figure 3A). Conversely, Hyper-O-GlcNAcylation
(Glucose and ThmG-treatment) of cells resulted in conspicuous F-actin staining throughout the
cytoplasm and stress fiber-like bundles along the marginal borders of the cells (white arrows,
Figure 3A), indicative of mesenchymal cell morphology.
Despite the observed morphological changes in Hypo- and Hyper-O-GlcNAcylated cells,
there was no evidence of changes in transcript abundance for key EMT markers (ZEB1, CDH1,
CDH2, CTNNB1, VIM, SNAI1, SNAI2, and CLDN1) among the treatment groups as assessed by
qPCR analysis (Table 2). Similarly, immunoblots indicated no change in E-Cadherin (CDH1)
expression compared to Control cells; (Figures 3B and 3C). Although, expression of the ECadherin suppressor, Snail, was supported by all treatments, Hyper-O-GlcNAcylation via ThmG
increased Snail expression to a greater extent than that of high glucose (p<0.05; ThmG vs.
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Glucose, respectively, Figure 3C). The expression of β-Catenin was down-regulated by Hypo-OGlcNAcylation (OSMI-1), while Hyper-O-GlcNAcylation (ThmG) sustained β-Catenin
expression (p<0.05; Figure 3C). Claudin-1, a major constituent of tight junction complexes, was
noticeably decreased by Hyper-O-GlcNAcylation (ThmG) and Hypo-O-GlcNAcylation (OSMI1) compared to Control cells (p<0.05; Figure 3B). None of the other detected EMT markers (NCadherin, ZO-1, Vimentin, Slug, ZEB1) were affected by O-GlcNAcylation status (p>0.05;
Figure 3B).
Microarray analysis corroborates dysregulation of O-GlcNAcylation as a mechanism of
EMT in endometrial cancer
The above-described phenotypic changes were supported by mRNA analysis of 86 genes
important to the process of EMT. The EMT RT2 Profiler PCR Array and GeneGlobe Data
Analysis Center analysis tool (Qiagen), was used to measure changes in gene expression (2 fold
or greater) compared to Control cells (Supp. Table 2). Three independent experiments yielded
the same mRNA expression profile for both Hyper-O-GlcNAcylation treatments, with increased
expression of FOXC2 and WNT5B, both promoters of EMT, and KRT14, a cytoskeletal
intermediate filament monomer (Figure 4). Hypo-O-GlcNAcylated cells also had increased
WNT5B and KRT14, however, Hypo-O-GlcNAcylation decreased the expression of AHNAK,
CALD1, FGFBP1, TGFB2, TFPI2 genes (Figure 4). The AHNAK, CALD1, and TGFB2 genes
are all typically up-regulated during EMT, while FGFBP1 and TFPI2 are commonly
downregulated during this process (Chang et al., 2016).
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Figure 1.

Figure 1: Meta-analysis of O-GlcNAc alteration in female cancers and Validation of global OGlcNAc modification in Ishikawa cells. Cancer genomics data analysis depicting a cross-cancer
O-GlcNAc enzyme (OGT, MGEA5) alteration summary of female cancers. [A] Histograms
depicting the level of gene amplification, mutation, or deletion in each data set. Data was mined
from the TCGA database and was analyzed with the cBioPortal web analysis tool. Of these 18
female cancer datasets, uterine/endometrial cancer ranked the highest for gene alterations of OGT
and MGEA5. [B] Box plots comparing the relative mRNA expression of OGT and MGEA5 in
patients with or without a diagnosis of diabetes mellitus (DM). Additional analysis of the data set
revealed that OGT and MGEA5 mRNA was more highly expressed in endometrial cancer patients
with DM. [C] Western Blot analysis of global O-GlcNAc modification, relative to total protein, in
whole cell Ishikawa lysates treated with the OGT inhibitor, OSMI-1, the OGA inhibitor, Thiamet-G,
or supplemented with 25mM Glucose. Both Glucose and Thiamet-G increased O-GlcNAcylation; no
O-GlcNAcylation was detected in the OSMI-1 treated cells.
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Figure 2.

Figure 2. O-GlcNAcylation is required for proliferation and migration of Ishikawa cells. [A] Representative images of the
effects of Thiamet-G, high glucose, OSMI-1, or vehicle on migration/proliferation of Ishikawa cells (10%FBS). “Wounds” were
imaged every 24 hours for 72 hours. [B] Quantitative data of the wound healing assay. Each bar in the graph represents the mean +/SEM of 3 biological replicates (n=3). An asterisk (*) indicates a significant difference (p<0.05) within a corresponding time point.
[C] Results for the wound-healing assay repeated under serum-free conditions for 18 hours. Bars depict the mean +/- SEM (n=3).
[D] Representative images of invasive cells following a Biocoat Matrigel Transwell Invasion assay (n=4). Purple foci depict
invasive cells. [E] Quantitative analysis of the invasion assay in which each bar represents the mean number of invaded cells (+/SEM) after 48 hours of culture. Different letters denote differences (p<0.05) among the treatments (n=4).
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Figure 3. Disruption to O-GlcNAc signaling alters cell morphology and EMT protein expression. Representative images of fixed
Ishikawa cells treated with OSMI-1, Thiamet-G, 25mM glucose, or vehicle for 48 hours. Immunofluorescent staining of actin with
phalloidin was asses for signs of EMT, including stress fibers (white arrows), and focal adhesions (yellow arrows). [B] Representative
images of Western Blot analysis (n=3) of whole cell lysates probed for epithelial and mesenchymal protein markers associated with EMT in
Ishikawa cells treated as stated above for 48 hours. [C] Densitometry analysis of Western Blots [B], bars represent the mean +/- SEM
(n=3), different letters denote statistically significant differences in density (p<0.05).
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Figure 4.

Figure 4. Disruption of O-GlcNAc alters gene expression in EMT related genes in Ishikawa
cells. Cells were cultured with OSMI-1, Thiamet-G, 25mM glucose, or vehicle for 48 hours before
being harvested for RNA isolation. The mRNA was the quantified by RT-PCR (n=3) and depicted is
relative expression of cells grown in [A] 25mM glucose, [B] Thiamet-G, and [C] OSMI-1 compared
to vehicle (control). The lines encompass 2-fold changes. Genes up-regulated are denoted by red
circles, whereas genes down-regulated appear as green circles. Black circles constitute genes that
were relatively unchanged. [D] The chart and heatmap summarize the results compared to anticipated
outcomes for EMT based upon the current literature.
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Table 1.
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Table 2.
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Discussion
O-GlcNAcylation is a recently discovered post-translational modification of cellular
proteins that is highly abundant and ubiquitous throughout the nuclear and cytoplasmic
compartments of the cell, yet its influence on cellular processes is poorly understood. Firstdiscovered about 30 years ago (Torres & Hart, 1984), O-GlcNAc is an end-product of the
hexosamine biosynthesis pathway (HBP), where its relative concentration serves as nutrient
sensor indicative of metabolic status(Palin et al., 2014). Indeed, elevated O-GlcNAcylation (i.e.,
Hyper- O-GlcNAcylation), for example, is a hallmark of high metabolism seen in many types of
cancers (Singh et al., 2015), including cancers of the breast (S a Caldwell et al., 2010),
liver(GUO et al., 2012), bladder (Rozanski et al., 2012), prostate (Itkonen et al., 2013), lung(Mi
et al., 2011), colon (Kamigaito et al., 2013; Mi et al., 2011), and endometrium(Krześlak et al.,
2012). Thus, O-GlcNAc, and by extension O-GlcNAcylation, may constitute an important
regulator of cancer development and progression, while simultaneously providing a potential,
novel connection between the onset of T2D and the increased risk of certain cancers (Gallagher
& LeRoith, 2015). Endometrial cancers fall into this category of increased risk attributable to
T2D (Byrne et al., 2014; Friberg et al., 2007; Zelenko & Gallagher, 2014), and the current study
is the first, to our knowledge, to reveal that aberrant O-GlcNAcylation mechanistically-augments
tumorigenicity of endometrial cancer cells.
One mechanism responsible for increased tumorigenicity in many cancers is the
phenomenon of epithelial-mesenchymal transition (EMT). Although most scientists
acknowledge that EMT is a critical process of embryogenesis, this same process enhances tumor
development and metastasis (Kondaveeti, Guttilla Reed, & White, 2015; Tam & Weinberg,
2013; Yilmaz & Christofori, 2009). Some of the key characteristics of EMT include the loss of
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cell polarity and cell-cell adhesions, and an increase in invasive properties (Larue & Bellacosa,
2005; Rojas-Puentes et al., 2016). In the current study, Hyper-O-GlcNAcylation supported cell
proliferation, induced reorganization of the cytoskeleton, and promoted invasion of endometrial
cancer (Ishikawa) cells.
Intercellular adhesion, mediated largely by cadherin and catenin proteins, is a critical
obstacle for epithelial cells to overcome as they de-differentiate and become more tumorigenic.
A decrease in E-Cadherin expression, for instance, is among the initiating steps of EMT (Onder
et al., 2008; Yao, Dai, & Peng, 2011), and is a notable consequence of Hyper-O-GlcNAcylation
in many cell types (Fardini et al., 2013). Snail1, an E-Cadherin suppressor, is stabilized by OGlcNAc at Ser112 under hyperglycemic culture conditions (Sang Yoon Park et al., 2010), and OGlcNAcylation of E-Cadherin can occur directly via the cytoplasmic domain, which
consequently inhibits its transport to the cell surface and prevents intercellular adhesion(Zhu et
al., 2012). In the current study, Hyper-O-GlcNAcylation increased the expression of Snail1, but
the effect was modest and had no overall impact on E-Cadherin expression or the expression of
any other EMT protein markers. This suggests that the alteration of E-Cadherin expression is
perhaps less critical for EMT in Ishikawa cells, or that the period of time required for this type of
transition is much longer than that evaluated in the current experiments (48 hrs).
A major group of cellular signaling pathways associated with EMT are the Wnt signaling
pathways. Of the Wnt pathways, 3 have been characterized; the canonical pathway, the
noncanonical pathway, and the noncanonical Wnt/Calcium pathway (Yilmaz & Christofori,
2009). In the canonical pathway, Wnt induces the expression of the mesenchymal-like protein,
Beta-catenin. Beta-catenin accumulates in the cytoplasm and is translocated to the nucleus,
where it acts as a transcriptional activator of TCF/LEF family transcription factors, which in turn
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induces a cellular response (Polakis, 2000). A recent study investigating the role of high glucose
concentrations in endometrial cancer found that high glucose increased the flux of glucose into
the HBP, in turn increasing O-GlcNAcylation of proteins (Zhou et al., 2016). Hyper-OGlcNAcylation also increased the expression of B-catenin (Zhou et al., 2016). In contrast, an
upregulation of the non-canonical Wnt ligand, WNT5B, by any form of O-GlcNAc dysregulation
(i.e., Hyper- and Hypo-O-GlcNAcylation), occurred in the current study, and this outcome did
not affect the canonical Wnt ligands (i.e. Wnts -1, -2, -3, -8a, -8b, -10a, -10b)(Siar et al., 2012) or
β-catenin expression (Figures 4 and 3B, respectively). The non-canonical Wnt pathways are not
as well understood as the canonical, partly due to the diversity and sheer number of pathways.
However, one such intracellular pathway activated by Wnt5b is the Planar Cell Polarity (PCP)
pathway, which controls tissue polarity and cell migration (Spandidos & Ethnikon Hidryma
Ereunōn, 1994). WNT5B is up-regulated in MCF-7 cells(Panepistēmio tēs Krētēs. & Katoh,
2002) and is associated with cell migration and proliferation in lung cancer cells (Harada et al.,
2016). In preadipocytes, WNT5B overexpression partially inhibits canonical Wnt/β-catenin
signaling, thereby promoting adipogenesis (Kanazawa et al., 2005). In addition to its role in
cancer and metastasis, non-canonical Wnt signaling also promotes metabolic dysfunction and
adipose tissue inflammation, which is critical to the development of insulin resistance (Fuster et
al., 2015). Collectively, these observations lead us to suggest that, in Ishikawa cells,
dysregulation of O-GlcNAc signaling promotes EMT through activation of non-canonical Wnt
signaling by WNT5B overexpression, which may in turn inhibit Wnt/β-catenin signaling. Such a
mechanism might also help explain the connection between insulin resistance and increased risk
of endometrial cancer.
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In addition to increased WNT5B expression, the transcription factor, Forkhead box
protein C2 (FOXC2) is highly-expressed in Hyper-O-GlcNAcylated Ishikawa cells. In
accordance with these results, there is often increased expression of FOXC2 during EMT, and
over-expression of FOXC2 is associated with highly-metastatic cancers (Hollier et al., 2013),
some of which can be reduced by shRNA therapy (Paranjape et al., 2016). In podocytes, for
instance, increased FOXC2 is associated with increased vimentin expression, cytoskeletal
reorganization, disruption to ZO-1 localization, and increased cell motility (Datta, Lindfors,
Miura, Saleem, & Lehtonen, 2016). Thus, there is support for the concept that Hyper-OGlcNAcylation of Ishikawa cells induces EMT and metastasis via a FOXC2-mediated
mechanism.
Cytoskeletal re-organization is key feature of EMT. Cytokeratin intermediate filaments
are often considered biomarkers of cancers, but are more frequently gaining attention as
mediators of disease (Karantza, 2011; Pan et al., 2013). Perhaps the best example of this is
Keratin 18, a component of cytokeratin 8/18 intermediate filaments, which has long been used as
a marker for apoptosis in cancers (Lomnytska & Souchelnytsky, 2007), but the loss of keratin 18
expression in cells is associated with EMT (Fortier et al., 2013a). In our previous work utilizing
cervical cancer cells, we determined that Hypo-O-GlcNAcylation reduces and re-organizes
cytokeratin 8/18 filaments, which suggests that O-GlcNAcylation influences filament expression
and stability (Jaskiewicz, et al, 2017). Similar results were noted in the current study, as both
Hyper- and Hypo-O-GlcNAcylation increased the expression of Keratin 14 mRNA in
endometrial cells. Others have shown that co-expression of vimentin and keratin in MCF-7
breast cancer cells increases cell invasiveness (Hendrix, Seftor, Seftor, & Trevort, 1997). HyperO-GlcNAcylation in Ishikawa cells in the current study increased Keratin 14 expression, had no
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effect on vimentin expression, and yet increased metastatic potential. These findings are
intriguing and warrant further investigation into the potential regulation of keratin filaments by
O-GlcNAcylation, and a possible role in disease progression.
In summary, dysregulation of O-GlcNAcylation supports EMT and cytoskeletal reorganization in endometrial cancer cells, potentially through activation of the noncanonical Wnt
signaling pathway by WNT5B. Additionally, Hyper-O-GlcNAcylation induces the expression of
FOXC2 and augments the invasion potential of the cells. These findings indicate Hyper-OGlcNAcylation, such as that observed in diabetic individuals (Medford et al., 2012), could
enhance the aggressiveness of endometrial cancer. Conversely, Hypo-O-GlcNAcylation impaired
endometrial cancer cell proliferation and wound healing, and down-regulated expression of proEMT genes (AHNAK, CALD1, and TGFB2). These observations suggest that metabolic status,
particularly as it relates to O-GlcNAcylation, might be an important consideration in therapeutic
approaches to endometrial cancer. Future studies should focus on aberrant O-GlcNAcylation as a
potential marker for more aggressive disease in human tissues, and the inhibition of Hyper-OGlcNAcylation as a potential treatment in diabetic patients.
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CHAPTER 5
HYPER-O-GLCNACYLATION IMPAIRS THE ANTI-PROLIFERATIVE AND ANTIINVASIVE PROPERTIES OF PROGESTERONE IN ENDOMETRIAL CANCER CELLS

Introduction
Hyper-O-GlcNAcylation of proteins is a subsequent artifact of metabolic disorder
(Keembiyehetty et al., 2015) and is indicative of many cancers (Ma & Vosseller, 2013; Onodera,
Nam, & Bissell, 2014), including endometrial cancer (Krześlak, Wójcik-Krowiranda, Forma,
Bieńkiewicz, & Bryś, 2012). While the incidence of most types of cancer has declined in the
U.S., endometrial cancer remains on the rise, disproportionately affecting black women (Cote,
Ruterbusch, Olson, Lu, & Ali-Fehmi, 2015). The mean age for onset of endometrial cancer is 60
years, but at least 14% of cases diagnosed are women of reproductive age (Evans-Metcalf,
Brooks, Reale, & Baker, 1998). These women have the option to postpone surgical treatment in
favor of fertility-sparing progestin therapy (Jeong-Yeol Park, 2015; Kesterson & Fanning, 2012;
Ramondetta, Burke, Broaddus, & Jhingran, 2006), but there are inevitable risks associated with
this alternative, including the risk for undiagnosed synchronous or metastatic cancer. In a metaanalysis of 27 studies, 76% of the women responded favorably to progestin treatment, however,
24% of these patients had recurring disease within 19 months post treatment (Ramirez,
Frumovitz, Bodurka, Sun, & Levenback, 2004). Additionally, many endometrial cancer patients
are obese and/or suffer from metabolic disorders like insulin resistance and hyper-glycemia
(Byrne et al., 2014), which results in global hyper-O-GlcNAcylation (Trinca & Hagan, 2017)
and can confound therapeutic approaches.
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Progesterone (P4) therapy reduces cell growth and invasion in endometrial cancer
through the up-regulation of the cyclin dependent kinase inhibitors, p21 and p27 (Dai, Wolf,
Litman, White, & Leslie, 2002; Shimizu et al., 2009); mechanisms that can also be influenced by
O-GlcNAcylation. The tumor suppressor, p27 is highly O-GlcNAcylated, and an O-GlcNAc
modification at Ser2 promotes the accumulation of p27 in the cytoplasm of HEK293 and
hepatocellular carcinoma (HCC) cell lines (Qiu et al., 2017). Furthermore, the PI3K/Akt pathway
is heavily influenced by O-GlcNAcylation (Gandy, Rountree, & Bijur, 2006; Jóźwiak, Forma,
Bryś, & Krześlak, 2014), and can regulate the expression of both p21 (Lawlor & Rotwein, 2000;
Rössig et al., 2001) and p27 (Graff et al., 2000) to further augment human cancers (Vivanco &
Sawyers, 2002).
In the current study, the objective was to investigate the influence of hyper-OGlcNAcylation on the efficacy of progestin therapy in endometrial cancer cells. Ishikawa cells
(an immortal endometrial cancer cell line) were exposed to the O-GlcNAcase inhibitor, ThiametG (ThmG), to induce hyper-O-GlcNAcylation and then test the efficacy of a therapeutic
concentration of P4 (100nM) to inhibit Ishikawa cell proliferation and invasion.
Materials and Methods
Cell Culture and Reagents. Endometrial cancer cells (Ishikawa) were obtained from Sigma
Aldrich (cat. #99040201). Cell Line authentication was performed before, during, and after
experimentation at the University of Vermont Cancer Center Advanced Genome Technologies
Core and was supported by the University of Vermont Cancer Center, Lake Champlain Cancer
Research Organization, and the University of Vermont College of Medicine. O-GlcNAcylation
within the cells was manipulated by the OGA inhibitor, ThmG (1μM, Fisher Scientific)
dissolved in DMSO (Fisher Scientific) at a concentration of 1000X. Control cells received an
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equivalent concentration (0.1%) of DMSO as vehicle. Progesterone was administered to cells at
100nM as reported by others (Dai et al., 2002), and dissolved in ethanol (0.1%). Cell culture
media (EMEM, 10% FBS and 10μl/mL antibiotic-anti-mycotic) (Fisher Scientific) was
supplemented with 10nM estradiol (E2, #E1132, Sigma,; a gift from Dr. Catherine Combelles,
Middlebury College) to support progesterone receptor expression as described (Holinka, Hata,
Kuramoto, & Gurpide, 1986). Culture medium was exchanged every 24 hours unless otherwise
specified.
Immunoblotting. Whole cell lysates of Ishikawa cells cultured in 25cm2 flasks (Corning,
Corning, NY) for 48 hours, were harvested by trypsin and lysed with RIPA buffer and passage
through a 26G needle. Proteins were then separated on pre-stained SDS-Page gels (BioRad,
Hercules, CA) and transferred to PVDF membrane. Membranes were then probed for global OGlcNAcylation (CST-O-GlcNAc 110.6 antibody; Cell Signaling Technology, Inc.; Beverly,
MA), p21 (p21 Waf1/Cip1 (12D1) Rabbit mAb #2947, Cell Signaling), and p27 (p27 Kip1
(D69C12) XP® Rabbit mAb #3686, Cell Signaling) proteins. Detection was achieved using
secondary antibody (Anti-rabbit IgG HRP-linked Antibody, Cell Signaling Technology, Inc.),
followed by Clarity Western ECL substrate (BioRad). Blots were imaged on the BioRad
ChemiDoc Imaging System, and densitometry was calculated with Image J.
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in duplicate
in flat-sided Thermo Fisher Scientific™ Nunc™ Cell Culture Tubes at an initial seeding density
of 50k cells/ml of culture medium. Treatment groups included cultures of cells continuously
exposed to vehicle (DMSO-Control), 1 μM Thiamet-G, and 100nM P4 accordingly. The
conditioned culture medium was exchanged without/with treatment daily, and the cells for each
group were harvested for counting at 24-hour intervals over a three-day period.
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Matrigel Invasion Assay. Corning Matrigel Biocoat Invasion Chambers (24 well, 0.8μ)
(Corning, Bedford, MA) were used to assess the invasion potential of treated cells compared to
control. The upper chamber was seeded with 100,000 serum-starved cells. Cells were exposed to
O-GlcNAc-modifying treatments and progesterone at the time of seeding. The lower chamber
contained 5% FBS as a chemoattractant. Cells were incubated for 48 hours at 37°C and 5% CO2.
Cells were then removed from the upper chamber and the Transwell membranes were fixed with
100% methanol and stained with Crystal Violet. Invaded cells were then counted by two
independent researchers and the results were averaged.
Results
Proliferation and Invasion.
A three-day cell proliferation assay confirmed the anti-proliferative effects of 100nM
progesterone reported in the literature (Dai et al., 2002), (p<0.05 P4 treatment extended the
doubling time by 21%; however, simultaneous treatment with ThmG negated this effect and
resulted in a doubling time comparable to control (19.50 +/- 0.48 hours vs. 19.52 +/- 0.35 hours,
respectively; Figure 1). In contrast, P4 did not decrease the invasion potential of Ishikawa cells
compared to control, however ThmG treatment with or without progesterone did increase the
invasiveness compared to progesterone treatment alone, (p<0.05, Figure 2).
Inhibition of OGA augments O-GlcNAcylation in Ishikawa cells; an effect impaired
by P4 and downregulation of OGT expression.
OGA inhibition by Thiamet-G increased O-GlcNAcylation by 3-fold compared to
control cells. Interestingly, and reduced OGT expression as reported in the literature.
Progesterone treatment reduced the expression of OGT compared to control, and this was further
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reduced by ThmG and P4 in combination. Subsequently, the level of O-GlcNAc modification
was also reduced compared to cells treated with ThmG alone (p<0.05, Figure 3).
Inhibition of OGA by ThmG, reduces PR A and B and p27 expression in Ishikawa cells.
Progesterone treatment maintained PR A and PR B expression while, hyper-OGlcNAcylation, induced by ThmG treatment, reduced both PR A and PR B expression (p<0.05),
even with progesterone treatment (p<0.05). Progesterone reduced p21 expression compared to
control cells (p<0.05, Figure 3). Interestingly, p21 expression was increased compared to control
cells in hyper-O-GlcNAcylated cells (ThmG) that were also treated with P4 (p<0.05, Figure 3).
Progesterone treatment maintained control levels of p27, but hyper-O-GlcNAcylation reduced
p27 expression compared to control cells, regardless of P4 treatment. However, p27 expression
was increased compared to ThmG treatment alone when P4 was added to the culture media
(p<0.05, Figure 3).
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Figure 1. [A] Growth curve depicting the average (n=3) daily total cell counts for cells
grown in control conditions (vehicle, DMSO and etOH), 100nM P4, 1μM ThmG, or a
combination of ThmG and P4. [B] Doubling time +/-SEM calculated from growth curve
data. [C] Representative images (n=3) of cell culture confluency at 24, 48, and 72 hours
imaged at 20X magnification. * Specifies statistical significance (p<0.05).
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Figure 2.
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Figure 2. [A] Representative images of Transwell invasion assay membranes (n=4), fixed
invasive cells stained with Crystal Violet (20X). [B] Bar graph denoting average (n=4)
percent invasive population counted by 2 independent researchers. Different letters denote
significant statistical differences (p<0.05).
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Discussion
Hyper-O-GlcNAcylation overcomes the inhibitory effects of progesterone therapy on cell
proliferation and invasion in Ishikawa cells.
Hyper-O-GlcNAcylation, particularly by the inhibition of OGA, increases cell
proliferation in many cell types (Fardini, Dehennaut, Lefebvre, & Issad, 2013). This includes our
own previous work in Ishikawa cells, discussed in Chapter 4. In the current study, OGA
inhibition by ThmG, increased O-GlcNAcylation and supported both proliferation and invasion
despite the therapeutic (i.e., inhibitory) effect of P4 treatment. Unlike previous studies (Dai,
Wolf, Litman, White, & Leslie, 2002; Shimizu et al., 2009), however, P4 in the current work had
no impact on cell invasion. This result is attributed to likelihood that OGA inhibition (via
ThmG) promoted cell invasion through mechanisms associated with Epithelial-to-Mesenchymal
Transition (EMT) as discussed in Chapter 4. In previous studies also conducted in Ishikawa cells,
P4 was found to reduce EMT in vitro, however loss of PR expression correlated with increased
EMT and more progressive disease (Van der Horst, et al., 2012).
Progesterone impairs OGT expression and subsequent O-GlcNAcylation
To our knowledge, the current study is the first to provide evidence that P4 impairs global
O-GlcNAcylation in endometrial cancer cells and this effect is associated with the reduction of
expression of O-GlcNAc cycling enzymes, namely OGT. P4 reduced the expression of OGT
both alone and in combination with the OGA inhibitor, ThmG. While the mechanism for this
effect is unclear, P4 does influence carbohydrate metabolism by inducing hyperinsulinemia and
promoting glycogen storage in the liver (Kalkhoff, 1982). In this manner, P4 could regulate the
amount of glucose shuttled to the Hexosamine Biosynthesis Pathway. A reduction of OGT
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expression is associated with reduced proliferation, adhesion, and migration of cells in a fetal
human cancer cell line (Steenackers et al., 2016). Thus, it is conceivable that the antiproliferative and anti-invasive effects of P4 are attributable to a reduction in OGT.
Progesterone Receptor expression is influenced by Progesterone and O-GlcNAcylation
Ishikawa cells expressed Progesterone Receptors A and B in all treatment types,
however, ThmG significantly reduced both PR A and PR B regardless of progesterone treatment.
A study conducted in 2003 established two stable Ishikawa cell lines, hPR A and hPR B
expressing cells, to study the individual effects of PR A and B receptors. Only the cells that
expressed PR B alone were growth responsive to progesterone treatment, while the PR A
expressing cells continued to proliferate (Smid-Koopman et al., n.d.). In breast cancer, PR A
tends to be predominantly expressed, leading to reduced progestin responsiveness (Graham et al.,
2005). In congruency with these observation, cell treated with ThmG exhibited reduced PR A
and PR B expression and continued to proliferate normally despite P4 treatment. This suggests
that the downregulation of PR by OGA inhibition and subsequent hyper-O-GlcNAcylation could
protect endometrial cancer cells from the effects of progestin treatment, and possibly even
promote growth.
P27 expression can be regulated by both P4 and Hyper-O-GlcNAcylation
The cyclin dependent kinase inhibitor, p27, is generally described as a tumor suppressor.
In this study, P4 treatment maintained the expression of p27 compared to control cells, however
in similar cell lines P4 promoted the expression of p27 (Dai et al., 2002). Alternatively, treatment
with the OGA inhibitor, ThmG, reduced the expression of p27. Decreased expression of p27 has
been related to poor prognosis in lung, esophageal, colon, breast, and prostate cancers, of which
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O-GlcNAcylation is also largely elevated (Abukhdeir & Park, 2008). When cells were treated
with P4 and ThmG in combination, p27 expression did increase, but did not return to control
levels (Figure 3).
In this instance, Hyper-O-GlcNAcylation did reduce the anti-proliferative effect of P4
through the reduction of p27 expression, which translated to an increase in cell proliferation
(Figure 1) despite P4 treatment. The tumor suppressor p27 is heavily O-GlcNAcylated (Ser2,
Ser106, Ser110, Thr157, and Thr198) in HEK293 cells and hepatocellular carcinoma (HCC)
cells. In these cells, O-GlcNAcylation and phosphorylation of p27 were found to have a dynamic
interplay. O-GlcNAcylation at Ser2 promoted the nuclear export of p27 and increased
phosphorylation of p27, both resulting in the accumulation of p27 in the cytoplasm, supporting
cell cycle progression (Qiu et al., 2017). Furthermore, increased Akt activity also contributes to
increased cell growth through a reduction p27 expression in prostate cancer (Graff et al., 2000),
and O-GlcNAcylation is a known activator of Akt signaling (Shi et al., 2012). Further work
should assess the nuclear and cytoplasmic expression of p27, as well as Akt activity to further
elucidate the mechanism by which OGA inhibition reduces p27 expression and maintains cell
cycle progression and proliferation.
Co-treatment with P4 and ThmG increase p21 expression in Ishikawa cells
In previous studies, P4 treatment had been shown to reduce cell proliferation in
endometrial cancer cells (Hec50) partially through the up-regulation of the cyclin-dependent
kinase inhibitors p21 and p27 (Dai et al., 2002). In contrast, similar experiments conducted in the
endometrial cancer cell line, Ishikawa, reduced p21 expression (Figure 3). In other studies
conducted in Ishikawa cells, p21 expression was found to be unchanged by estradiol,
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progesterone, or hCG (Abıke et al., 2013). Despite the lack of p21 expression, the proliferation
rate remained notably reduced in cells treated with P4 (Figure 1, p<0.05), suggesting that the
inhibition of cell proliferation in P4 treated cells was not related to the expression of cyclindependent kinase inhibitors. However, when cells were treated with both P4 and ThmG, p21
expression was increased. A possible explanation for this is that progesterone activates the p21
promoter through an Sp1 site. O-GlcNAcylation of Sp1 may stabilize and activate Sp1 (Ma &
Vosseller, 2014), which could in turn promote p21 expression. The expression and function of
p21 can be altered through phosphorylation by Akt. In endothelial cells, activated Akt
phosphorylates p21, which results in its reduced ability to inhibit Cdk2 activity, presumably by
inhibiting p21/cdk2 complex binding (Rössig et al., 2001). This suggests that hyper-OGlcNAcylation may promote the phosphorylation of p21 by Akt, thus impairing its antiproliferative function.
Conclusion
While these results are intriguing, it’s clear that the relationship between PR and OGlcNAcylation is complex and warrants further study. We suggest the following experiments to
continue this investigation: 1) quantitative cell cycle analysis 2) assessment of cell
viability/apoptosis, and 3) further investigation into the potential relationship between OGlcNAcylation and progesterone and Akt signaling. Understanding the impact O-GlcNAcylation
may have on the anti-proliferative and anti-invasive effects of progestin could have significant
implications for the treatment of female cancers. Such knowledge could lead to improved
treatment protocols and prognoses for patients struggling with metabolic disease and cancers.
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In the present work, global O-GlcNAcylation in cells was manipulated by
pharmacological inhibition of O-GlcNAc cycling enzymes to better understand its influence on
tumorigenic potential in female cancers. While there is significant literature exists discussing the
role of O-GlcNAcylation in breast and ovarian cancer, very little attention has been paid to
cervical and endometrial cancer, despite their connection to metabolic disorders. As such, this
research project fills an important gap in our literary knowledge, making a modest yet substantial
contribution to the fields of glycobiology and reproductive oncology. The finding that Hyper-OGlcNAcylation consistently supports a more tumorigenic phenotype in multiple cell lines
confirms the importance for understanding how nutrition and metabolic health influence chronic
disease. This topic will continue to be of great importance to human health as the obesity
epidemic progresses (Conway et al., 2018).
While basic science cell culture based studies like this one are critical first steps in
understanding molecular mechanisms of disease, they are not without limitations. We must first
consider the cell culture model. The SiHa and Ishikawa cell lines utilized for this work are
immortalized cell lines that have been cultured for extended periods of time. It is well known
that as cells remain in culture, they begin to adapt to the aqueous culture conditions and behave
very differently than cells in vivo (Kaur & Dufour, 2012). Thus it is important that these cell
culture studies be interpreted as such. It is also important to note that no two cell lines are alike,
and despite being the same tissue type, different cell lines can produce different results. For
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example, the preliminary work for chapters 2 and 3 was completed with the well know cervical
cancer cell line, HeLa. While these cells provided interesting and unique results, in surprising
contrast to SiHa cells, it was discovered that HeLa cells had undergone such drastic mutation that
they were no longer a reliable model of cervical cancer (Landry et al., 2013). In future studies we
set out to use multiple cell lines to further validate our work. We originally selected Ishikawa
and ECC-1 cells for the experiments described in Chapters 4 and 5, however, genomic validation
of the cell lines revealed they were in fact the same cell line (Korch et al., 2012), likely a result
of earlier contamination or misidentification. As you can see, there are many potential pitfalls
associated with cell culture experimentation; however, it is a critical tool for the early
development of studies that lend to progressive work with primary tissues and in vivo models.
Additional consideration should be given to use of pharmacological inhibitors. While they
are a relatively simple, rapid, and cost-effective way to study the function of a protein, they are
not without drawbacks. When working with small molecule inhibitors it is critical to be aware of
the specificity of the inhibitor. Inhibitors that do not have a proven selectivity can have
unintended effects on cell function, which can over shadow experimental results. An example of
this is discussed in chapters 1 and 2, is the OGT inhibitor Alloxan, which was later discovered to
have cytotoxic effects beyond the inhibition of OGT. Those experiments were later repeated with
the new, more specific small molecule inhibitor, OSMI-1 (Chapter 3). A complimentary
technique for validating data collected with a small molecule inhibitor would be the use of
knockdown approaches such as si- or shRNA (D. D. Rao et al., 2009) which reduce the
expression of the associated genes.
The difficulties presented by the nature of O-GlcNAc modification have been difficult to
overcome, but in just over three decades the tools and techniques available to researchers have
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grown exponentially, and they likely will continue to do so. Although our laboratory has a
particular interest in cytoskeletal filaments, this collection of work focused on global whole-cell
O-GlcNAcylation. While this type of broad analysis is vital for our understanding of this nutrient
sensing modification, it is my hope that future work will progress to focus on specific proteins
and modification sites of interest. As mentioned in chapter 1, this type of work has been done
with the implementation of genomic point mutation techniques. With the increased availability
of CRISPR/Cas9 gene editing technology this type of research will likely continue to expand,
and could potentially lead minimally invasive treatments for O-GlcNAc related diseases.
O-GlcNAcylation’s influence on cell metabolism has made it a hot topic issue in diabetes
and cancer research, leading to expansive literature; however, there are many areas of human and
animal health where O-GlcNAcylation has only minimally been addressed. One such area of
interest is mammalian reproduction. Despite a significant connection between metabolic
syndrome and reproductive health (Al Awlaqi et al., 2016), O-GlcNAc is not currently on the
radar of researchers. Literature on the topic is nearly non-existent, for example, a PubMed search
produces only one publication mentioning O-GlcNAcylation in granulosa cells; “Transcriptome
profiling of granulosa cells of bovine ovarian follicles during growth from small to large antral
size follicles” (Hatzirodos et al., 2014). This study, published in 2014, identified the OGA
encoding gene, MGEA5, as a regulator of small follicles, and found it to be down-regulated in
large follicles. This suggests that O-GlcNAcylation is an important component in
folliculogenesis; however, this concept has not been studied further.
Similarly, there are many aspects of male reproduction that could be influenced by OGlcNAcylation. For example, many of the same molecules and mechanisms critical to the EMT
phenotype, the subject of chapter 4, are also critical in maintaining the Blood-Testes-Barrier
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(TBT) (Mruk & Cheng, 2015). This includes, Notch signaling, PI3K, Occludins, claudins, βcatenin, N-Cadherin, and ZO-1. As such, it would be surprising if dysregulation of OGlcNAcylation did not have an influence on sertoli cells, and subsequently the BTB.
Additionally, “leaking” in the BTB is often associated with heat stress, which is implicated in
many areas both male and female infertility (Hansen, 2009). As previously mentioned, OGlcNAcylation is upregulated during times of cellular stress or injury. Stress induced OGlcNAcylation promotes cell survival through regulation of: PI3K/Akt pathway, heat shock
protein expression, calcium homeostasis, levels of reactive oxygen species, ER stress, protein
stability, mitochondrial dynamics, and inflammation (Groves et al., 2013). Any of these
mechanisms could have a significant influence on reproductive health. Heat stress is of particular
concern in livestock species. Given this, understanding the role O-GlcNAcylation may play in
the heat stress response could be crucial to agricultural species management, especially as we
begin to face the realities of climate change (Sheikh et al., 2017).
Another environmental issue impacting reproduction is our pervasive exposure to
environmental chemicals. Many of these chemicals have been shown to influence cell
metabolism. Some notable examples include, Bisphenol A, PBDE (a category of flame
retardants), some pesticides (DDT/DDE), and PFOA (Heindel et al., 2017), an industrial
byproduct that has recently been discovered in the drinking water of many Vermonters. While
these chemicals are already on the radar of many, there potential connection to disrupted OGlcNAc signaling have not been explored, and could be crucial in understanding the full impact
these chemicals have on reproductive and metabolic health.
While this project presented me with many challenges and moments of frustration, this
work has only fed my intrigue and excitement for glycobiology. I am grateful to have had the
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experience of working in a new and excited field, and am especially aware of the unique and rich
research opportunities that lay before me as I begin my career in academia. My appreciation for
glycobiology has also become a component of my career goals as an educator. As an
undergraduate I received minimal to no education in glycoscience, and I am shocked by the lack
of glycobiology educational opportunities even at the graduate level. In 2012, the National
Academies published a report at the request of the NIH, NSF, DOE, FDA, and the Howard
Hughes Medical Institute, investigating the current state of the Glycosciences (Council, 2012).
The report found that despite the obvious importance of glycobiology in all aspects of human
and animal health, glycoscience is viewed as a niche research area, with limited funding or
investment. While this is due to a variety of reasons stemming from the complex nature of the
problem, the committee noted specifically, “a pervasive lack of knowledge by nonglycoscientists, at all levels of education, about these types of molecules,” (Hart, 2012). I plan to
approach my career as a researcher and an educator with at the fore front of my mind. I hope to
share my enthusiasm for glycobiology with my students and colleagues in the classroom,
laboratory and conference halls.
In conclusion, this body of work contributes significant interdisciplinary findings to the fields
of reproduction, cancer biology, and glycobiology. It also provides clear scaffolding for future
research in this and related areas of study. The process of compiling this work has illuminated
my drastic evolution from an inexperienced graduate student to a productive, independent
research scientist. I have acquired a diverse set of both technical and cognitive skills that have
prepared me for a career as a scientist and educator, and I am grateful for further opportunities to
learn and grow that are presented in a career academia.
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